dacarbazine and Disease Exacerbation

dacarbazine has been researched along with Disease Exacerbation in 333 studies

Research

Studies (333)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	11 (3.30)	18.2507
2000's	122 (36.64)	29.6817
2010's	193 (57.96)	24.3611
2020's	7 (2.10)	2.80

Authors

Authors	Studies
Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M; Tamura, Y; Yanagisawa, S	1
Ali, N; El Nabarawy, NM; Hussein, H; Salah, Z; Selim, M; Sidhom, I	1
Baues, C; Borchmann, P; Diehl, V; Dietlein, M; Dührsen, U; Eich, H; Engert, A; Fuchs, M; Goergen, H; Greil, R; Hertenstein, B; Keller, UB; Kobe, C; Krause, SW; Kuhnert, G; Lohri, A; Maschmeyer, G; Meissner, J; Rosenwald, A; Sasse, S; Schäfer, E; Soekler, M; Thiemer, J; Topp, MS; Viardot, A; Vogelhuber, M; von Tresckow, B; Wilhelm, M; Zijlstra, JM	1
Ascierto, PA; Blank, CU; Chapman, PB; D'Amelio, A; Demidov, LV; Dutriaux, C; Gasal, E; Grob, JJ; Gutzmer, R; Haas, T; Hauschild, A; Kefford, R; Kiecker, F; Lebbé, C; Millward, M; Mookerjee, B; Ribas, A; Rutkowski, P; Schadendorf, D	1
André, MPE; Bellei, M; Brice, P; Brière, J; Carde, P; Casasnovas, O; Clément-Filliatre, L; Depaus, J; Douxfils, J; Dupuis, J; Federico, M; Fortpied, C; Gianni, AM; Gobbi, PG; Heczko, M; Hutchings, M; Iannitto, E; Mounier, N; Rambaldi, A; Valagussa, P; Viviani, S; Zinzani, PL	1
Fujii, H; Goda, S; Hiraoka, N; Matsumoto, Y; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Sugitani, M; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T	1
Advani, RH; Barr, PM; Batlevi, CL; Budde, E; Caron, P; Casulo, C; Constine, LS; Dandapani, SV; Drill, E; Drullinsky, P; Friedberg, JW; Grieve, C; Hamilton, A; Hamlin, PA; Hoppe, RT; Horwitz, SM; Joseph, A; Khan, N; Kumar, A; Laraque, L; Matasar, MJ; Moskowitz, AJ; Moskowitz, CH; Noy, A; Palomba, ML; Schöder, H; Straus, DJ; Vemuri, S; Yahalom, J; Yang, J; Younes, A; Zelenetz, AD	1
Caroli-Bosc, FX; Cauchin, E; Dumars, C; Foubert, F; Girot, P; Matysiak-Budnik, T; Mosnier, JF; Muzellec, L; Regenet, N; Senellart, H; Touchefeu, Y	1
Baumert, BG; Blumenthal, DT; Brown, PD; Burt Nabors, L; Corn, BW; Erridge, SC; Gilbert, MR; Golfinopoulos, V; Gorlia, T; Hegi, ME; Hyun Nam, D; Kim, MM; Mason, WP; Mehta, MP; Mirimanoff, RO; Perry, JR; Reardon, DA; Stupp, R; van den Bent, MJ; Weller, M; Zhang, P	1
Kang, CS; Lv, SG; Wang, QX; Wu, MJ; Xiao, B; Xu, B; Ye, MH; Zhu, XG	1
Fan, X; Lan, T; Qu, Y; Song, Y; Wang, H; Yu, C; Zhan, Q; Zhang, M; Zhang, Z; Zhao, Z	1
Trogrlić, D; Trogrlić, I; Trogrlić, Z	1
Brillant, C; Engert, A; Monsef, I; Skoetz, N; von Tresckow, B; Will, A	1
Choi, SH; Kim, E; Kim, IH; Kim, JW; Kim, TM; Lee, ST; Park, CK; Wee, CW; Yoo, RE	1
Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J	1
Hama, S; Kawamata, T; Kurisu, K; Muragaki, Y; Nosaka, R; Onishi, S; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F	1
Allen, PJ; Basturk, O; Capanu, M; Chou, JF; Do, RKG; Horvat, N; Klimstra, DS; Raj, N; Reidy-Lagunes, D; Zhang, L	1
Choi, CG; Jung, SC; Kim, HS; Kim, HW; Kim, JH; Kim, SJ; Park, JE; Ryu, KH; Shim, WH	1
Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL	1
Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T	1
Abou Yehia, Z; Akhtari, M; Chuang, H; Dabaja, BS; Dong, W; Fanale, M; Fayad, LE; Garg, N; Gunther, JR; Hagemeister, FB; Lee, HJ; Mawlawi, O; Milgrom, SA; Oki, Y; Osborne, EM; Pinnix, CC; Reddy, JP; Rohren, E; Smith, GL	1
Chaskis, E; De Witte, O; Devriendt, D; Goldman, S; Lefranc, F; Luce, S; Minichini, V; Sadeghi, N	1
Aoki, K; Asai, N; Enomoto, A; Han, YP; Kato, A; Kato, T; Mii, S; Momota, H; Murakumo, Y; Natsume, A; Ogawa, S; Ohka, F; Shiraki, Y; Suzuki, H; Takahashi, M; Todo, T; Ushida, K; Wakabayashi, T	1
Atkins, MB; Flaherty, LE; Kirkwood, JM; Moon, J; Othus, M; Ribas, A; Samlowski, WE; Sondak, VK; Witter, M	1
Adeberg, S; Bernhardt, D; Bougatf, N; Combs, SE; Debus, J; Haberer, T; Harrabi, SB; Herfarth, K; Paul, A; Rieken, S; Uhl, M; Unterberg, A; Verma, V; Wick, W	1
Choi, SH; Kang, KM; Kim, JH; Lim, WH; Nam, JG; Sohn, CH; Yoo, RE; Yun, TJ	1
Andrews, DW; Blumenthal, DT; Brown, PD; Dignam, JJ; Gilbert, MR; Hopkins, K; Howard, SP; Lessard, N; Mehta, MP; Scannell Bryan, M; Shi, W; Souhami, L; Tzuk-Shina, T; Valeinis, E; Werner-Wasik, M; Youssef, EF	1
Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA	1
Bupathi, M; Chen, JL; Hays, JL	1
Azab, AK; Fettig, N; Goddu, SM; Jin, A; Kapoor, V; Luderer, MJ; Muz, B; Puente, P; Rogers, B; Salama, NN; Shah, S; Shoghi, K; Thotala, D; Tsien, C	1
Aman, A; Cseh, O; Jensen, KV; Luchman, HA; Weiss, S	1
Caruntu, C; Constantin, C; Neagu, M; Surcel, M; Zurac, S	1
Ellis, J; Hertel, N; Johnson, H; Lee, D; Meng, Y; Morais, E; Philips, Z; Roskell, N; Walker, A	1
Amsbaugh, M; Boakye, M; Burton, E; Hattab, EM; Nelson, M; Ugiliweneza, B; Williams, B; Woo, S; Yusuf, M	1
Araki, T; Kawasaki, H; Kusumoto, K; Ohata, K; Shigematsu, K; Shigeno, M; Takeshita, S	1
Banerjee, S; Bhattacharyya, S; Biswas, N; Majumder, B; Mitra, D; Murmu, N; Mustafi, SM; Ray, S	1
Arance, A; Ascierto, PA; Atkinson, V; Brady, B; Charles, J; Chiarion-Sileni, V; Cognetti, F; Di Giacomo, AM; Dutriaux, C; Gogas, H; Hassel, JC; Hernberg, MM; Jiang, J; Kalinka-Warzocha, E; Lebbé, C; Long, GV; Mauch, C; McNeil, C; Mihalcioiu, C; Mortier, L; Ny, L; Rizzo, J; Robert, C; Rutkowski, P; Saci, A; Savage, KJ; Schadendorf, D; Svane, IM	1
Agarwal, A; Jain, R; Kumar, S; Mikkelsen, T; Narang, J; Poptani, H; Schultz, L; Siddiqui, S; Wang, S	1
Kruser, TJ; Mehta, MP; Robins, HI	1
Angelini, C; Arosio, P; Bertuzzi, A; Colombo, P; Cucchiari, D; De Sanctis, R; Faucher, E; Fusco, N; Pellegrinelli, A	1
Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E	1
Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C	1
Araki, N; Hide, T; Hirayama, M; Kobayashi, D; Komohara, Y; Kuratsu, J; Makino, K; Midorikawa, U; Mizuguchi, S; Nagai, M; Nagayama, M; Nakamura, H; Niibori-Nambu, A; Takeya, M; Takezaki, T; Tsubota, N	1
Choi, SH; Chu, HH; Jung, SC; Kim, IH; Kim, JH; Kim, SC; Kim, TM; Lee, AL; Lee, SH; Park, CK; Park, SH; Ryoo, I; Shin, H; Sohn, CH; Yeom, JA; Yoon, TJ	1
Chin, K; Kotapati, S; Sherrill, B; Wang, J	1
Abdollahi, M; Nikfar, S; Teimouri, F	1
Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P	1
Amoroso, D; Andreuccetti, M; Falcone, A; Fontana, A; Galli, C; Galli, L; Landi, L; Lombardi, G; Porta, C; Zagonel, V; Zustovich, F	1
Agostinis, P; Govaere, O; Gremeaux, L; Maes, H; Roskams, T; Stas, M; Van den Broeck, A; van den Oord, JJ; Vankelecom, H; Wouters, J	1
Aldave, G; de Gallego, J; Díez-Valle, R; Domínguez, PD; Gállego Pérez-Larraya, J; Marigil, M; Tejada, S	1
Cerhova, J; Chakravarti, A; Engellandt, K; Geiger, KD; Juratli, TA; Krex, D; Lautenschlaeger, T; Schackert, G; von Kummer, R	1
Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY	1
Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W	1
Madlon-Kay, R; Patel, M; Raza, A; Skubitz, K; Vakil, K; Zakharova, M	1
Kerr, J; Reyes, C; Satram-Hoang, S; Stepanski, EJ; Walker, MS	1
Egle, A; Greil, R; Grundbichler, M; Hufnagl, C; Magnes, T; Melchardt, T; Moik, M; Strasser, M; Weiss, L	1
Bozzao, A; De Sanctis, V; Enrici, RM; Lanzetta, G; Minniti, G; Osti, M; Romano, A; Scaringi, C; Valeriani, M	1
Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY	1
Abramson, DH; Albertini, MR; Ambrosini, G; Ancell, K; Bluth, M; Carvajal, RD; Chapman, PB; Dickson, MA; Doyle, A; Erinjeri, J; Flynn, PJ; Gajewski, TF; Hedvat, C; Joshua, AM; Kudchadkar, RR; Lao, CD; Lawson, DH; Lewis, K; Linette, GP; Lutzky, J; Marr, B; Milhem, MM; Panageas, KS; Quevedo, JF; Sato, T; Schwartz, GK; Sosman, JA; Wolchok, JD	1
Anderson, CM; Bayouth, JE; Buatti, JM; Capizzano, AA; Clerkin, PP; Magnotta, V; McGuire, SM; Morris, A; Muruganandham, M; Smith, BJ; Smith, MC	1
Fields, B; Macomson, S; Mansour, J; Rixe, O	1
Bloch, O; Oh, T; Parsa, AT; Rutkowski, MJ; Safaee, M; Sayegh, ET; Sun, MZ; Tihan, T	1
Hyodo, A; Nagaishi, M; Sugiura, Y; Suzuki, K; Takano, I; Tanaka, Y; Yokoo, H	1
Ajlan, A; Recht, L	1
Asklund, T; Birgander, R; Brynolfsson, P; Garpebring, A; Hauksson, J; Henriksson, R; Karlsson, M; Nilsson, D; Nyholm, T; Trygg, J	1
Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yun, TJ	1
Belizário, JE; de Andrade-Lima, LC; Garcia, CC; Menck, CF; Munford, V; Quinet, A; Rocha, CR; Vieira, DB	1
Cai, J; Chang, L; Chen, L; Cui, Y; Dou, Z; Du, W; Jiang, C; Liu, X; Liu, Y; Wang, G; Wang, H; Wang, X; Yi, L; Zhang, P	1
Berger, MS; Bollen, AW; Breshears, JD; Cotter, JA; Ivan, ME; Theodosopoulos, PV	1
Hirohata, T; Ishii, Y; Matsuno, A	1
Attinà, G; Balducci, M; Caldarelli, M; Colosimo, C; Lazzareschi, I; Mastrangelo, S; Maurizi, P; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A; Scalzone, M	1
Beal, K; Martinez, N; Omuro, A; Prager, AJ; Young, RJ; Zhang, Z	1
Kim, HR; Kim, KH; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Seol, HJ	1
Curran, W; Dignam, JJ; Gilbert, MR; Mehta, M; Wang, M; Won, M	1
Ganesan, P; Ganesan, TS; Kannan, K; Krishnakumar, R; Lakshmipathy, KM; Mahajan, V; Radhakrishnan, V; Rajaraman, S; Rajendranath, R; Sagar, TG; Sundersingh, S; Udupa, K	1
Aburatani, H; Aihara, K; Berger, MS; Chang, SM; Costello, JF; Fouse, SD; Hallbeck, M; Heimans, JJ; Hong, C; Johnson, BE; Kloezeman, JJ; Lamfers, ML; Malmström, A; Mazor, T; Molinaro, AM; Mukasa, A; Reijneveld, JC; Saito, N; Söderkvist, P; Stenmark-Askmalm, M; Taylor, BS; van Thuijl, HF; Wesseling, P; Ylstra, B	1
Becq, J; Bentley, D; Benz, SC; Birkbak, NJ; Brada, M; Dietrich, PY; Eklund, AC; Favero, F; Forshew, T; Gerlinger, M; Grocok, RJ; Gutteridge, A; Humphray, S; Kingsbury, Z; McGranahan, N; Peden, JF; Roger, S; Rowan, A; Salm, M; Sanborn, JZ; Spencer-Dene, B; Stamp, G; Swanton, C; Szallasi, Z	1
Bernard, B; Cogdell, DE; Fuller, GN; Granberg, KJ; Hu, L; Ji, P; Nykter, M; Shmulevich, I; Sun, Y; Turner, KM; Yli-Harja, O; Yung, WK; Zhang, W; Zhou, X	1
Faião-Flores, F; Fruet, AC; Maria, DA; Maria-Engler, SS; Pardi, PC; Quincoces Suarez, JA	1
Nagane, M	1
Arita, N; Chiba, Y; Hashimoto, N; Hosen, N; Izumoto, S; Kagawa, N; Kijima, N; Kinoshita, M; Morimoto, S; Morita, S; Nakajima, H; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Sugiyama, H; Tsuboi, A; Yoshimine, T	1
Eloy, JA; Liu, JK; Patel, J	1
Sonoda, Y	1
Jancalek, R; Kazda, T; Laack, NN; Pospisil, P; Prochazka, T; Sevela, O; Slampa, P; Vrzal, M	1
Schiff, D	1
Boucard, C; Chinot, O; Delfino, C; Denicolai, E; Figarella-Branger, D; Graillon, T; Metellus, P; Nanni, I; Ouafik, L; Padovani, L; Tabouret, E; Tchoghandjian, A	1
Barrington, S; Brownell, A; Counsell, N; Culligan, D; Hancock, B; Hoskin, P; Illidge, T; Johnson, P; Kruger, A; Lister, A; McMillan, A; O'Doherty, M; Pettengell, R; Popova, B; Radford, J; Smith, P; Wimperis, J	1
Kovic, B; Xie, F	1
Bottomley, A; Chinot, OL; Cloughesy, T; Henriksson, R; Hilton, M; Mason, WP; Nishikawa, R; Ravelo, A; Saran, F; Taphoorn, MJ; Theodore-Oklota, C; Wick, W	1
Barbeau, LM; Granton, PV; Paesmans, K; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S	1
Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ	1
Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J	1
Arevalo-Perez, J; Kaley, T; Lyo, J; Peck, KK; Shi, W; Thomas, AA; Young, RJ; Zhang, Z	1
Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ	1
Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S	1
Fukushima, S; Kiyohara, Y; Namikawa, K; Okuyama, R; Otsuka, Y; Shibagaki, N; Tokudome, T; Tsutsumida, A; Uchi, H; Uhara, H; Yamazaki, N	1
Burrows, SH; Mannari, D	1
Kang, S; Li, Y; Shi, Y; Sun, Y; Tao, Y; Zhou, L	1
Dullea, A; Marignol, L	1
Aller, J; Campderá, M; Estrada, J; Lilienfeld, H; Magallón, R; Martín, P; Palacios, N; Saucedo, G	1
Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ	1
Cao, Y; Sun, J; Yang, X; Zhang, W	1
Fukuhara, N; Harigae, H; Ichikawa, S; Ichinohasama, R; Katsushima, H; Takahashi, T	1
Chinot, OL; Cloughesy, T; Dhar, S; Garcia, J; Henriksson, R; Mason, W; Nishikawa, R; Pozzi, E; Saran, F; Wick, W	1
Chen, K; Chen, TC; Groshen, SL; Hofman, FM; Jhaveri, N; Kota, R; Kushal, S; Olenyuk, BZ; Shih, JC; Vaikari, VP; Wang, W; Yeh, TS	1
Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L	1
Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H	1
Cai, J; Chen, B; Feng, Y; Han, B; Jiang, C; Li, J; Li, Q; Li, R; Li, Y; Sun, Y; Tian, Y; Wang, G; Yi, L	1
Abrams, KR; Amonkar, MM; Bell, H; Casey, M; Latimer, NR	1
Al-Sarraj, S; Bridges, LR; Burford, A; Carceller, F; Fowkes, LA; Hovestadt, V; Jerome, N; Jones, C; Jones, DT; Khabra, K; Koh, DM; Laxton, R; Leach, MO; Mackay, A; Mandeville, H; Marshall, LV; Moreno, L; Pearson, AD; Pfister, SM; Saran, F; Vaidya, S; Zacharoulis, S	1
Cantero, D; Hernandez-Lain, A; Hilario, A; Perez-Nuñez, A; Ramos, A; Sepulveda, JM	1
Eich, HT; Kriz, J	1
Ahn, KJ; Chang, JH; Cho, SJ; Cho, YH; Chung, DS; Gwak, HS; Hong, CK; Hong, YK; Hwang, SC; Jung, TY; Kang, MK; Kang, SG; Kang, SH; Kim, BS; Kim, CY; Kim, EH; Kim, EY; Kim, IA; Kim, IH; Kim, JH; Kim, SH; Kim, TM; Lee, KH; Lee, SH; Lee, SI; Lee, YS; Lim, DH; Nam, DH; Park, CK; Seol, HJ; Song, JH; Suh, CO; Yoo, H; Yoon, SM	1
Hertenstein, A; Hielscher, T; Menn, O; Platten, M; Wick, A; Wick, W; Wiestler, B; Winkler, F	1
Choi, CG; Kim, C; Kim, HS; Kim, JH; Kim, SJ; Shim, WH	1
Blaes, J; Dong, Z; Green, E; Hertenstein, A; Jugold, M; Lemke, D; Löw, S; Ott, M; Platten, M; Pledl, HW; Sahm, F; Steffen, AC; Weiler, M; Wick, W; Winkler, F; Zorn, M	1
Bendszus, M; Chinot, OL; Cloughesy, T; Henriksson, R; Kerloeguen, Y; Mason, W; Nishikawa, R; Revil, C; Saran, F; Wick, W	1
Berger, MS; Butowski, N; Chang, SM; Clarke, JL; Costello, JF; Dayal, M; Haas-Kogan, DA; Lin, Y; Molinaro, AM; Nelson, S; Perry, A; Phillips, JJ; Prados, M; Wahl, M	1
Engel, D; Flüh, C; Hattermann, K; Held-Feindt, J; Mehdorn, HM; Mentlein, R; Synowitz, M	1
Agati, P; Agostinelli, C; Argnani, L; Biggi, A; Borra, A; Broccoli, A; d'Amore, F; Fanti, S; Fuligni, F; Gallamini, A; Gascoyne, RD; Hamilton-Dutoit, S; Kamper, P; Kulikowski, W; Levis, A; Małkowski, B; Merli, F; Patti, C; Piccaluga, PP; Pileri, SA; Rigacci, L; Romano, A; Rybka, J; Sista, MT; Steidl, C; Stelitano, C; Stracqualursi, L; Subocz, E; Tajer, J; Trentin, L; Tripodo, C; Vitolo, U; Zaucha, JM; Zinzani, PL	1
Cheng, G; Li, H; Li, J; Li, X; Zhang, J	1
Choi, SH; Kim, BR; Kim, IH; Kim, JH; Kim, TM; Lee, ST; Park, CK; Park, SH; Park, SW; Sohn, CH; Yun, TJ	1
Fan, B; Jiao, BH; Jing, SY; Sun, GZ; Tong, J; Wang, F; Yang, JK; Yang, JP	1
Bao, X; Dai, C; Deng, K; Feng, M; Lian, W; Liu, X; Ma, S; Ma, W; Sun, B; Wang, R; Wang, Y; Xing, B; Yao, Y; Zhong, D	1
Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A	1
Akhtari, M; Chuang, H; Dabaja, BS; Dong, W; Fanale, M; Garg, N; Gunther, JR; Khoury, JD; Mawlawi, O; Milgrom, SA; Oki, Y; Osborne, EM; Pinnix, CC; Reddy, JP; Rohren, E; Smith, GL; Suki, T; Yehia, ZA	1
Chang, JH; Chang, JS; Cho, JH; Choi, SH; Kim, JW; Kim, SH; Suh, CO	1
Beck, J; Belmonte-Beitia, J; Bodnar, M; Bogdańska, MU; Murek, M; Pérez-García, VM; Schucht, P	1
Guo, Y; Kong, X; Ma, W; Wang, R; Wang, Y	1
Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C	1
Ugurel, S	1
Bar-Eli, M; Lev, DC; Melnikova, VO; Villares, GJ; Zigler, M	1
Black, PM; Bracht, LK; Drappatz, J; Hornick, JL; Kesari, S; Kulke, MH; LaFrankie, DC; Meyerhardt, JA; Norden, A; Redston, M; Wen, P	1
Cao, Y; Gomez-Hassan, D; Hayman, J; Junck, L; Lawrence, TS; Lee, IH; Piert, M; Rogers, L; Ten Haken, RK; Tsien, C	1
Arusell, R; Brown, PD; Buckner, JC; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Jenkins, RB; Kitange, G; Krishnan, S; Kugler, JW; Mischel, P; Morton, RF; Rowland, KM; Sarkaria, JN; Scheithauer, BW; Schiff, D; Uhm, JH; Wu, W; Yong, WH	1
Chaskis, C; De Ridder, M; Everaert, H; Michotte, A; Neyns, B	1
Gerstner, ER; Lafrankie, D; McNamara, MB; Norden, AD; Wen, PY	1
Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W	1
Berger, W; Dehoux, M; DeNeve, N; Gaussin, JF; Kiss, R; Lefranc, F; Martin de Lassalle, E; Mathieu, V; Mijatovic, T; Pirker, C; Vernier, M	1
Batchelor, TT; Cahill, DP; Codd, PJ; Curry, WT; Louis, DN	1
Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Fisher, B; Gijtenbeek, J; Gorlia, T; Hau, P; Hegi, ME; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Vecht, CJ; Villa, S; Weller, M; Wesseling, P	1
Akasaka, H; Fujimoto, K; Ito, R; Kitazawa, S; Kodaka, T; Koizumi, N; Kondo, T; Kusama, T; Sakano, S; Takahashi, K; Tsunemine, H; Yamamura, H	1
Beith, J; Davis, ID; Haydon, A; Hayward, O; Hersey, P; Kefford, R; Lorigan, P; Margison, GP; McArthur, G; McGown, G; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Thomson, D; Thorncroft, M; Watson, AJ	1
Abrey, LE; Clarke, JL; DeAngelis, LM; Gavrilovic, I; Hormigo, A; Iwamoto, FM; Karimi, S; Lassman, AB; Nolan, CP; Panageas, K; Sul, J	1
Couvelard, A; Faivre, S; Hammel, P; Hentic, O; Larroque, B; Lévy, P; Maire, F; Raymond, E; Ruszniewski, P; Yapur, L; Zappa, M	1
Cognetti, F; Di Giovanni, S; Fabi, A; Metro, G; Russillo, M; Vidiri, A	1
Arora, B; Dutta, D; Gupta, T; Jalali, R; Kurkure, P; Munshi, A; Raut, N; Sarin, R	1
Brockmann, MA; Hermes, P; Kohlhof, P; Neumaier-Probst, E; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P; VON Deimling, A	1
Anile, C; Apicella, G; Balducci, M; Cellini, N; Colicchio, G; D'Agostino, GR; De Bari, B; De Renzi, F; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Pompucci, A; Valentini, V	1
Brandsma, D; van den Bent, MJ	1
Cairncross, JG; de Robles, PA; Dharmawardene, M; Easaw, JC; Forsyth, PA; Hamilton, MG; Magliocco, AM; McIntyre, JB; Parney, IF; Roldán, GB; Scott, JN; Yan, ES	1
Baron, MH; Bauchet, L; Bernier, V; Capelle, L; Duffau, H; Fontaine, D; Guyotat, J; Mandonnet, E; Pallud, J; Peruzzi, P; Taillandier, L	1
Choi, JR; Jang, SJ; Kim, SH; Kim, SJ; Lee, CH; Lee, ST; Park, TS; Song, J; Suh, B	1
Bamberg, M; Engel, C; Ernemann, U; Felsberg, J; Hartmann, C; Ketter, R; Koeppen, S; Kortmann, RD; Meisner, C; Meyermann, R; Pietsch, T; Rapp, M; Reifenberger, G; Sabel, MC; Stockhammer, F; Stoffels, M; von Deimling, A; Weller, M; Wick, W; Wiestler, OD	1
Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C	1
Lavini, C; Majoie, CBLM; Reijneveld, JC; Richel, DJ; Stalpers, LJA; van Furth, WR; van Linde, ME; Verhoeff, JJC	1
Atkins, KA; Ferriss, JS; Jazaeri, AA; Lachance, JA; Modesitt, SC	1
Aviv, R; Davey, P; Lam, K; Morrison, M; Perry, J; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN	1
Freyschlag, CF; Krafft, U; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F	1
Fathallah-Shaykh, HM; Fiveash, JB; Gillespie, GY; Gladson, CL; Huang, Z; Johnson, MJ; Kekan, MS; Kuo, H; Markert, JM; Meleth, S; Nabors, LB	1
Wen, PY	1
Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B	1
Hernberg, M; Ivaska, J; Laukka, M; Lundin, J; Pyrhönen, S; Tyynelä, K; Vihinen, PP; Vuoristo, MS	1
Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK	1
Butowski, NA; Cha, S; Chang, SM; Elkhaled, A; Jalbert, L; Khayal, IS; Nelson, SJ; Polley, MY	1
Choe, GY; Han, JH; Kang, HC; Kim, CY; Kim, IA; Kim, JH	1
Eto, T; Nakashima, S; Ogo, E; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M; Tokutomi, T	1
Barone, G; Lazzareschi, I; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A	1
Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC	1
Huang, CY; Kuo, LT; Lien, HC; Liu, KL; Liu, MT; Tseng, HM	1
Dosa, E; Kraemer, DF; Neuwelt, EA; Thompson, EM	1
Agarwala, S; Bedikian, AY; Conry, R; DeConti, RC; Ernstoff, M; Kim, KB; Papadopoulos, N	1
Drabick, JJ; Fateh, S; Gingrich, R; Neves, RI; Schell, TD	1
Butowski, NA; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Nelson, SJ; Polley, MY	1
Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IA; Kim, IH; Kim, JE; Kim, JH; Kim, TM; Kim, YJ; Lee, SH; Nam, DH; Paek, SH; Park, BJ; Park, CK; Rhee, CH	1
Choi, SH; Han, JH; Jung, HW; Kim, CY; Kim, DG; Kim, J; Kim, SK; Kim, TM; Lee, AR; Lee, SH; Park, CK; Park, SH; Yim, SY	1
Payer, F	1
Abbasova, EV; Govorina, EV; Parkhomenko, RA; Rodionov, MV; Shcherbenko, OI; Zelinskaia, NI	1
Busch, C; Knappskog, S; Oberg, K; Sebjornsen, S; Sorbye, H; Welin, S	1
Pazos Arias, B; Peteiro Cancelo, A; Romero Reinoso, C; Samprón Rodríguez, M; Vello Román, A	1
Abe, K; Amano, T; Hiwatashi, A; Honda, H; Kamano, H; Nakamizo, A; Shioyama, Y; Shirakawa, Y; Suzuki, S; Torisu, R; Yamashita, K; Yoshimoto, K; Yoshiura, T	1
Cuneo, KC; Desjardins, A; Friedman, HS; Kirkpatrick, JP; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Willett, CG	1
Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J	1
García, S; Garzás, C; Izquierdo, L; López-Laso, E; Mateos, ME; Pérez-Navero, JL	1
Aldape, K; Chang, SM; Chen, A; Cloughesy, TF; de Groot, JF; Deangelis, LM; Gilbert, MR; Jackson, EF; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Yao, J; Yung, WK	1
Abrey, LE; Aldape, KD; Ashby, LS; Cairncross, JG; Chamberlain, MC; Cloughesy, TF; DeAngelis, LM; Eichler, AF; Fisher, BJ; Green, RM; Iwamoto, FM; Jhanwar, SC; Kamar, FG; Lassman, AB; Ligon, KL; Louis, DN; Mason, WP; Paleologos, NA; Panageas, KS; Rivera, AL; Robins, HI; Rocque, BG; Roldán, GB; Rosenblum, MK; Schiff, D; Weaver, SA; Wen, PY	1
Baurain, JF; Bondarenko, I; Chen, TT; Davidson, N; Francis, S; Garbe, C; Gascon, P; Grob, JJ; Harmankaya, K; Hauschild, A; Hoos, A; Humphrey, R; Ibrahim, R; Lebbe, C; Lotem, M; Maio, M; Miller, WH; O'Day, S; Richards, J; Robert, C; Testori, A; Thomas, L; Weber, J; Wolchok, JD	1
Abastado, JP; Audebourg, A; Avril, MF; Caignard, A; Garcette, M; Molina, TJ; Nardin, A; Prévost-Blondel, A; Tissier, F; Tow, C; Wong, WC	1
Aviv, R; Davey, P; Lam, K; Oh, J; Perry, JR; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN	1
Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J	1
Berberat, J; Bodis, S; Merlo, A; Rogers, S	1
Johnson, PW; Lim, SH	1
Butowski, N; Chang, SM; Clarke, JL; Lamborn, KR; Polley, MY; Prados, M	1
Borchmann, P; Diehl, V; Engert, A	1
Berdel, C; Fleckenstein, J; Ketter, R; Licht, N; Niewald, M; Rübe, C	1
Drecoll, U; Garbe, C; Hauschild, A; Hofmann, MA; Kaatz, M; Mohr, P; Schadendorf, D; Tilgen, W; Trefzer, U; Ulrich, J; Weichenthal, M	1
Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F	1
Dzhabarov, FR; Nepomniashchaia, EM; Pozdniakova, VV; Rozenko, LIa	1
Aoyama, H; Hirata, K; Houkin, K; Kobayashi, H; Murata, J; Narita, T; Onodera, S; Shiga, T; Tanaka, S; Terasaka, S	1
Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Lipp, ES; McLendon, R; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ	1
Easaw, JC; Roldán Urgoiti, GB; Singh, AD	1
Andrés, R; Balañá, C; Benavides, M; de Las Peñas, R; Fernández-Chacón, C; Gallego, O; García-Velasco, A; Gil, MJ; Herrero, A; Martínez-García, M; Mesia, C; Pérez-Martin, X; Peréz-Segura, P; Quintanar, T; Reynés, G	1
Filss, C; Glas, M; Hadizadeh, DR; Herrlinger, U; Kuchelmeister, K; Langen, KJ; Mack, F; Pietsch, T; Schäfer, N; Schüller, H; Scorzin, J; Simon, M; Stuplich, M; Urbach, H	1
Abo-Madyan, Y; Giordano, FA; Welzel, G; Wenz, F	1
Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S	1
Burns, DK; Chen, J; Kernie, SG; Li, Y; McKay, RM; Parada, LF; Yu, TS	1
Dreyer, C; Faivre, S; Raymond, E	1
Federspiel, B; Hansen, CP; Kjaer, A; Knigge, U; Langer, SW; Olsen, IH; Sørensen, JB	1
Beal, K; Chan, TA; Gutin, PH; Lassman, AB; Reyngold, M; Yamada, Y	1
Hoshimaru, M; Kawanabe, Y; Kihara, S; Koizumi, T; Sasaki, N; Sawada, M; Ueda, S; Yukawa, H	1
Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R	1
Bressel, M; Gunjur, A; Ryan, G	1
Hewer, E; Kappeler, A; Reinert, MM; Vajtai, I; Vassella, E	1
Fujii, T; Saito, N; Takahashi, K; Tanaka, M; Todo, T; Tsuno, NH	1
Ding, W; Jiang, H; Li, WP; Qian, C; Wu, BJ; Zhou, ZW	1
Consales, A; Garrè, ML; Morana, G; Nozza, P; Piccardo, A; Rossi, A	1
Chong, DQ; Chua, ET; Lim, KH; Ng, WH; See, SJ; Tan, SH; Tham, CK; Thomas, J	1
Berhorn, T; Blau, T; Dunkl, V; Fink, GR; Galldiks, N; Schroeter, M	1
Andreo, FC; Navarro, JT; Ribera, JM; Torrent, A	1
Choi, SH; Heo, DS; Jung, HW; Kim, IH; Kim, TM; Lee, SH; Park, CK; Park, SH	1
Alacacioglu, A; Canpolat, S; Coskun, A; Karatas, A; Oztekin, O; Postaci, H; Sop, G; Unal, S; Yurt, A	1
Nohgawa, M; Sugiyama, T; Yonetani, N	1
Dieckmann, K; Fazeny-Dörner, B; Hainfellner, J; Marosi, C; Piribauer, M; Rössler, K; Ungersböck, K; Veitl, M; Wenzel, C	1
Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ	1
Ariza, A; Balaña, C; Ballester, R; Mendez, P; Ramirez, JL; Rosell, R; Roussos, Y; Sanchez, JJ; Sarries, C; Taron, M	1
Neville, F; Nystrom, ML; Oliver, RT; Shamash, J; Steele, JP	1
Ames, P; Boasberg, PD; Deck, R; Kristedja, TS; Martin, M; O'Day, SJ; Petrovich, Z; Shinn, K; Tamar, B; Wang, H	1
Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK	1
Allgeier, A; Brandes, AA; Chinot, O; Frenay, M; Gorlia, T; Kros, JM; Menten, J; Stupp, R; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, ChJ	1
Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N	1
Boissevain, F; De Wit, M; Diehl, V; Duhmke, E; Engert, A; Hasenclever, D; Herrmann, R; Josting, A; Koch, P; Loffler, M; Mezger, J; Muller, RP; Muller-Hermelink, HK; Pfistner, B; Renner, H; Schiller, P; Schmidt, BF; Sieber, M; Willich, N; Wolf, J	1
Brown, P; Buckner, J	1
Calvet, D; Delattre, JY; Janoray, P; Rojas-Marcos, I	1
Aoki, T; Hashimoto, N; Ishikawa, M; Mizutani, T; Sugiyama, K	1
Baumert, BG; Stupp, R	1
Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P	1
Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A	1
Abdulkarim, B; Armand, JP; Cioloca, C; Djafari, L; Djazouli, K; Faivre, S; Guillamo, JS; Osorio, M; Parker, F; Raymond, E; Vera, K	1
Boiardi, A; Broggi, G; Eoli, M; Lamperti, E; Maccagnano, E; Salmaggi, A; Silvani, A	1
Eigentler, TK; Garbe, C	1
Agarwala, SS; Kirkwood, JM; Neuberg, D; Park, Y	1
Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK	1
Chamberlain, MC; Groshen, S; Tsao-Wei, DD	1
Ashley, DL; Cher, L; Rosenthal, MA	1
Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W	1
Bonadonna, G; Bonfante, V; Di Russo, A; Valagussa, P; Villani, F; Viviani, S	1
Couanet, D; Grill, J; Kalifa, C; Lelouch-Tubiana, A; Vassal, G; Verschuur, AC	1
Chamberlain, MC	1
Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S	1
Gomori, JM; Levin, N; Siegal, T	1
de Bruin, HG; de Wit, MC; Eijkenboom, W; Sillevis Smitt, PA; van den Bent, MJ	1
Bafaloukos, D; Briassoulis, E; Christodoulou, C; Fountzilas, G; Gogas, H; Hatzichristou, H; Kalofonos, HP; Linardou, H; Panagiotou, P; Tsoutsos, D	1
Alba, E; de Las Nieves, MA; Gumá, J; Herrero, J; Llanos, M; Márquez, A; Miramón, J; Rueda Domínguez, A	1
Afra, D; Sipos, L; Vitanovics, D	1
Balcerska, A; Balwierz, W; Chybicka, A; Depowska, T; Drozyńska, E; Kaczmarek-Kanold, M; Klekawka, T; Kowalczyk, J; Kołakowska-Mrozowska, B; Kołtan, A; Krawczuk-Rybak, M; Krenke, K; Matysiak, M; Moryl-Bujakowska, A; Moszant, A; Odój, T; Raś, M; Sońta-Jakimczyk, D; Sopyło, B; Stanuch, H; Stolarska, M; Wachowiak, J; Wysocki, M	1
Allgeier, A; Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Curschmann, J; Eisenhauer, E; Fisher, B; Gorlia, T; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Weller, M	1
Antonadou, D; Athanassiou, H; Beroukas, K; Karageorgis, P; Maragoudakis, E; Misailidou, D; Paraskevaidis, M; Saris, G; Synodinou, M; Verigos, C	1
Bafaloukos, DI; Brountzos, EN; Kelekis, DA; Panagiotou, IE; Papathanasiou, MA	1
Langer, CJ; Somer, RA	1
Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A	1
Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC	1
Bonadonna, G; Bonfante, V; Gianni, AM; Valagussa, P; Viviani, S	1
Chinot, O	1
Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I	1
Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R	1
Bökkerink, JP; Claviez, A; Dörffel, W; Körholz, D; Lüders, H; Mann, G; Pötter, R; Riepenhausen, M; Rühl, U; Scheel-Walter, HG; Schellong, G	1
Bogdahn, U; Koch, HJ; Kuchelmeister, K; Roeber, S; Schachenmayr, W; Schäfer, C; Steinbrecher, A; Villarrubia, V; Zimmermann, UW	1
Arnold, R; Hofbauer, L; Rinke, A; Schmidt, Ch	1
Bigner, DD; Birch, R; Brem, H; Dancey, JE; Delaney, SM; Desjardins, A; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Maxwell, J; McLendon, RE; Moschel, RC; Pegg, AE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, J; Sampson, JH; Tourt-Uhlig, S; Vredenburgh, J; Weingart, J	1
Aronson, F; Kennedy, T; Ready, N; Wanebo, H	1
Cohen, MH; Johnson, JR; Pazdur, R	1
Buff, E; Leimgruber, A; Maeder, PP; Meuli, RA; Ostermann, S; Stupp, R; Yeon, EJ	1
Allen, R; Ames, P; Cook, M; Cruickshank, S; Deck, R; Gonzalez, R; Good, J; Meyer, J; O'Day, S; Rose, M; Spitler, LE; Timmerman, M; Trautvetter, S; Weber, RW	1
Clawson, S; Cullen, MH; Hancock, BW; Jack, AS; Johnson, PW; MacLennan, KA; Radford, JA; Ryder, D; Smith, P; Stenning, SP; Sydes, MR; Walewski, J	1
Barbarisi, M; Moraci, A; Moraci, M; Parlato, C	1
Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF	1
Gilbert, MR	1
Bokstein, F; Fellig, Y; Fuchs, D; Lavon, I; Levin, N; Siegal, T; Zelikovitsh, B	1
Bordeleau, L; Charpentier, D; Crump, M; Eisenhauer, E; Matthews, S; Trudeau, ME; Yelle, L	1
Combs, SE; Debus, J; Edler, L; Haselmann, R; Heeger, S; Schulz-Ertner, D	1
Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E	1
Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS	1
Audebert, F; Hartmann, P; Kullmann, F; Schneidewind, A; Schölmerich, J	1
Ekmekcioglu, S; Fok, JY; Mehta, K	1
Argon, D; Basa, S; Seçkinel, SA; Tecimer, T; Varol, A	1
Landi, A; Piccirilli, M; Salvati, M	1
Bedikian, AY; Conry, R; DeConti, R; Gore, M; Haluska, FG; Hersey, P; Hersh, EM; Kirkwood, JM; Millward, M; Pavlick, AC; Pehamberger, H; Trefzer, U	1
Bertorelle, R; Biscuola, M; Blatt, V; Brandes, AA; Cavallo, G; Crinò, L; Ermani, M; Franceschi, E; Gioia, V; Tosoni, A	1
Boissevain, F; Diehl, V; Dühmke, E; Eich, HT; Engert, A; Haverkamp, H; Klimm, B; Koch, P; Lohri, A; Müller, RP; Müller-Hermelink, K; Pfistner, B; Trenn, G; Worst, P	1
Benouaich-Amiel, A; Crinière, E; Delattre, JY; Everhard, S; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Lejeune, J; Marie, Y; Mokhtari, K; Sanson, M; Thillet, J	1
Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR	1
Gergely, L; Illés, A; Keresztes, K; Miltényi, Z; Ress, Z; Simon, Z; Vadász, G; Váróczy, L	1
Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ	1
Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS	1
Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W	1
Agarwala, SS; Cai, C; Gooding, WE; Kirkwood, JM; Tarhini, AA	1
Connors, JM; Ding, K; Djurfeldt, MS; Gospodarowicz, MK; Horning, SJ; Macdonald, DA; Meyer, RM; Pearcey, RG; Shepherd, LE; Wells, WA; Winter, JN	1
Bomanji, J; Buchler, T; Edwards, SG; Lee, SM; Ramsay, A	1
Boiardi, A; Botturi, A; Broggi, G; Di Meco, F; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Solari, A	1
da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G	1
Bischof, M; Combs, SE; Debus, J; Edler, L; Nagy, M; Rausch, R; Schulz-Ertner, D; Welzel, T	1
Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A	1
Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ	1
Khan, OA; Levitt, NC; Margison, GP; Michael, M; Middleton, MR; Midgley, R; Mortimer, P; Olver, I; Ranson, M; Watson, AJ	1
Brandsma, D; Bromberg, JE; de Bruin, HG; Smitt, PA; Swaak-Kragten, AT; Taal, W; van den Bent, MJ; van Es, CA	1
Andrieu, JM; Brice, P; Colonna, P; Gastaut, JA; Lévy, R; Raphaël, M; Taillan, B; Tourani, JM	1
Berman, M; Blessing, JA; Currie, JL; McGehee, R; Soper, JT	1
Corry, J; Laidlaw, C; Liew, KH; Matthews, J; Wirth, A	1
Burg, G; Dummer, R; Flace, A; Meyer, JC; Seifert, B; Wimmer, I	1
Bedikian, A; Buzaid, AC; Eton, O; Legha, SS; Papadopoulos, N; Plager, C; Ring, S	1
Akande, N; Ali-Osman, F; Bedikian, A; Benjamin, RS; Buzaid, AC; Eton, O; Grimm, EA; Lee, JJ; Legha, SS; Papadopoulos, N; Plager, C	1
Bisighini, G; Di Lernia, V; Lo Scocco, G	1
Bischoff, H; Diehl, V; Dühmke, E; Engert, A; Franklin, J; Georgii, A; Glunz, A; Haedicke, C; Hasenclever, D; Hermann, R; Holmer, L; Krause, S; Lathan, B; Loeffler, M; Paulus, U; Pfreundschuh, M; Rüffer, JU; Sextro, M; Sieber, M; Stappert-Jahn, U; Tesch, H; von Kalle, K; Winnerlein-Trump, E; Wolf, J; Wulf, G	1
Agarwala, SS; Ferri, W; Gooding, W; Kirkwood, JM	1
Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M	1
Andersson, LC; Blomqvist, CP; Böhling, TO; Huuhtanen, RL; Tribukait, B; Virolainen, MJ; Wiklund, TA	1
Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N	1
Brada, M; Osoba, D; Prados, M; Yung, WK	1
Garaci, E; Izzo, F; Pierimarchi, P; Ranuzzi, M; Rasi, G; Sinibaldi-Vallebona, P; Terzoli, E; Tuthill, C	1
Enk, AH; Knop, J; Nashan, D; Rübben, A	1
Busstra, MB; Catsburg, T; Lang, MS; Mickisch, GH; Schröder, FH; van Brussel, JP	1
Yung, WK	1
Brada, M; Osoba, D; Prados, MD; Yung, WK	1
Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R	1
Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S	1
Abrey, LE; Boutros, DY; Mack, M; Malkin, MG; Olson, JD; Raizer, JJ; Rodavitch, A	1
Amicucci, G; Deraco, M; Fiorentini, G; Guadagni, S; Miotto, D; Palumbo, G; Pilati, PL; Rossi, CR; Russo, F; Santinami, M; Valenti, M	1
Anderson, C; Becker, M; Gatlin, K; Gibbs, P; Gonzalez, R; LaClaire, S; O'Driscoll, M; Pearlman, N; Stephens, J	1
Babović, N; Jelić, S; Kreacić, M; Matković, S; Popov, I; Stamatović, L	1
Carde, P; Cavalli, F; Diehl, V; Franklin, J	1
Bajetta, E; Beretta, E; Bombardieri, E; Buzzoni, R; Catena, L; Celio, L; Di Bartolomeo, M; Ferrari, L; Ferrario, E; Martinetti, A; Procopio, G; Seregni, E; Vitali, M	1
Croteau, D; Mikkelsen, T	1

Reviews

30 review(s) available for dacarbazine and Disease Exacerbation

Article	Year
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. Cancer medicine, 2020, Volume: 9, Issue:18 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dacarbazine; Disease Progression; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Procarbazine; Progression-Free Survival; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Vinblastine; Vincristine; Young Adult	2020
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. The Cochrane database of systematic reviews, 2017, 05-25, Volume: 5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Disease Progression; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Middle Aged; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Vinblastine; Vincristine; Young Adult	2017
Procarbazine, lomustine and vincristine for recurrent high-grade glioma. The Cochrane database of systematic reviews, 2017, 07-26, Volume: 7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Glioma; Humans; Hydroxyurea; Lomustine; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Procarbazine; Randomized Controlled Trials as Topic; Temozolomide; Vincristine	2017
Rectal Paraganglioma. Internal medicine (Tokyo, Japan), 2019, Jan-15, Volume: 58, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colonoscopy; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Disease Progression; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paraganglioma; Rectal Neoplasms; Reoperation; Vincristine	2019
Pseudoprogression after glioma therapy: a comprehensive review. Expert review of neurotherapeutics, 2013, Volume: 13, Issue:4 Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioma; Humans; Neoplasm Recurrence, Local; Radiation Injuries; Radiotherapy; Temozolomide	2013
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. Melanoma research, 2013, Volume: 23, Issue:5 Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Humans; Melanoma; Odds Ratio; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Skin Neoplasms; Temozolomide; Time Factors; Treatment Outcome	2013
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. Journal of neuro-oncology, 2014, Volume: 118, Issue:3 Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Evidence-Based Medicine; Glioblastoma; Humans; Temozolomide	2014
Supratentorial low-grade diffuse astrocytoma: medical management. Seminars in oncology, 2014, Volume: 41, Issue:4 Topics: Antineoplastic Agents; Astrocytoma; Dacarbazine; Disease Progression; Humans; Neoplasm Grading; Nitrosourea Compounds; Prognosis; Supratentorial Neoplasms; Temozolomide	2014
Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. Neurologia medico-chirurgica, 2014, Volume: 54, Issue:12 Topics: Adenoma; Administration, Oral; Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; Combined Modality Therapy; Dacarbazine; Disease Progression; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pituitary Gland; Pituitary Hormones; Pituitary Neoplasms; Temozolomide	2014
Dose-dense temozolomide: is it still promising? Neurologia medico-chirurgica, 2015, Volume: 55, Issue:1 Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Glioblastoma; Humans; Recurrence; Temozolomide	2015
The role of temozolomide in the treatment of aggressive pituitary tumors. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:6 Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Disease Progression; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Humans; Mutation; Neoplasm Recurrence, Local; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins	2015
Low-grade gliomas. Continuum (Minneapolis, Minn.), 2015, Volume: 21, Issue:2 Neuro-on Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioma; Humans; Isocitrate Dehydrogenase; Lomustine; Mutation; Procarbazine; Temozolomide; Treatment Outcome; Vincristine	2015
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jul-10, Volume: 33, Issue:20 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Canada; Chemoradiotherapy; Cost-Benefit Analysis; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Costs; Glioblastoma; Health Resources; Humans; Kaplan-Meier Estimate; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Temozolomide; Time Factors; Treatment Outcome	2015
MGMT testing allows for personalised therapy in the temozolomide era. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:1 Topics: Aged; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; Gene Silencing; Humans; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Precision Medicine; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Treatment Outcome	2016
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. American journal of clinical dermatology, 2008, Volume: 9, Issue:5 Topics: Antibodies, Monoclonal; Antineoplastic Agents; CD146 Antigen; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Immunotherapy; Interleukin-8; Melanoma; Neoplasm Metastasis; Skin Neoplasms	2008
Pseudoprogression and pseudoresponse in the treatment of gliomas. Current opinion in neurology, 2009, Volume: 22, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma; Humans; Radionuclide Imaging; Temozolomide; Treatment Outcome	2009
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme]. Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:1-2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diagnosis, Differential; Diagnostic Imaging; Diffusion Magnetic Resonance Imaging; Disease Progression; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Positron-Emission Tomography; Radiation Injuries; Sensitivity and Specificity; Temozolomide; Tumor Burden	2011
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme]. Magyar onkologia, 2012, Volume: 56, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Disease Progression; Drug Approval; Europe; Glioblastoma; Humans; Hungary; Irinotecan; Magnetic Resonance Imaging; Off-Label Use; Recurrence; Temozolomide; Treatment Outcome	2012
[Therapy of malignant melanoma at the stage of distant metastasis]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2004, Volume: 55, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine	2004
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology, 2004, Aug-10, Volume: 63, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cohort Studies; Combined Modality Therapy; Contrast Media; Cranial Irradiation; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease Progression; Female; Follow-Up Studies; Gadolinium; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Patient Selection; Procarbazine; Temozolomide; Vincristine	2004
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer investigation, 2005, Volume: 23, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Cognition Disorders; Dacarbazine; Disease Progression; Endpoint Determination; Glioblastoma; Health Status; Humans; Neuropsychological Tests; Procarbazine; Quality of Life; Survival Analysis; Temozolomide	2005
[New place of the chemotherapy in gliomas]. Bulletin du cancer, 2005, Volume: 92, Issue:4 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Glioblastoma; Humans; Prognosis; Survival Rate; Temozolomide	2005
Endocrine tumours of the gastrointestinal tract: Chemotherapy. Best practice & research. Clinical gastroenterology, 2005, Volume: 19, Issue:4 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cell Differentiation; Dacarbazine; Disease Progression; Gastrointestinal Neoplasms; Humans; Pancreatic Neoplasms; Streptozocin	2005
Advances in the treatment of primary brain tumors: dawn of a new era? Current oncology reports, 2006, Volume: 8, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Temozolomide	2006
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. The Lancet. Oncology, 2008, Volume: 9, Issue:5 Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Endothelial Cells; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Magnetic Resonance Imaging; Necrosis; Neoplasm Recurrence, Local; Patient Selection; Radiation Injuries; Radiotherapy, Adjuvant; Risk Assessment; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor A	2008
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. Leukemia & lymphoma, 1995, Volume: 16, Issue:5-6 Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4 Lymphocyte Count; Cohort Studies; Combined Modality Therapy; Comorbidity; Dacarbazine; Disease Progression; Doxorubicin; Female; France; Herpesviridae Infections; Herpesvirus 4, Human; HIV Infections; Hodgkin Disease; Homosexuality, Male; Humans; Life Tables; Lymphoma, AIDS-Related; Male; Mechlorethamine; Middle Aged; Prednisone; Procarbazine; Radioisotope Teletherapy; Registries; Remission Induction; Risk Factors; Substance Abuse, Intravenous; Survival Analysis; Tumor Virus Infections; Vinblastine; Vincristine	1995
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9 Suppl 5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Prednisone; Procarbazine; Survival Rate; Treatment Outcome; Vinblastine; Vincristine	1998
Temozolomide in malignant gliomas. Seminars in oncology, 2000, Volume: 27, Issue:3 Suppl 6 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease Progression; Glioblastoma; Humans; Quality of Life; Temozolomide	2000
Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease? The hematology journal : the official journal of the European Haematology Association, 2000, Volume: 1, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hodgkin Disease; Humans; Infertility; Mechlorethamine; Prednisolone; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Safety; Treatment Outcome; Vinblastine; Vincristine	2000
Adults with newly diagnosed high-grade gliomas. Current treatment options in oncology, 2001, Volume: 2, Issue:6 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Contraindications; Cranial Irradiation; Craniotomy; Dacarbazine; Disease Progression; Epidemiologic Methods; Glioblastoma; Humans; Isotretinoin; Lomustine; Palliative Care; Procarbazine; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Temozolomide; Treatment Outcome; Vincristine	2001

Trials

128 trial(s) available for dacarbazine and Disease Exacerbation

Article	Year
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 11-01, Volume: 37, Issue:31 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemoradiotherapy; Clinical Decision-Making; Dacarbazine; Disease Progression; Doxorubicin; Europe; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Progression-Free Survival; Radiotherapy Dosage; Time Factors; Vinblastine; Young Adult	2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. European journal of cancer (Oxford, England : 1990), 2020, Volume: 125 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; Imidazoles; Male; Melanoma; Middle Aged; Oximes; Patient Selection; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Young Adult	2020
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. International journal of radiation oncology, biology, physics, 2017, 05-01, Volume: 98, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Communication; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quality of Life; Radiation Dose Hypofractionation; Radiosurgery; Surveys and Questionnaires; Survivors; Temozolomide; Treatment Outcome	2017
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Temozolomide; Time Factors; Treatment Outcome; Young Adult	2017
High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer medicine, 2017, Volume: 6, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Recombinant Proteins; Retrospective Studies; Skin Neoplasms; Skin Ulcer; Survival Rate; Vinblastine	2017
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. International journal of radiation oncology, biology, physics, 2018, 01-01, Volume: 100, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Re-Irradiation; Salvage Therapy; Temozolomide; Time Factors	2018
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. The European journal of health economics : HEPAC : health economics in prevention and care, 2018, Volume: 19, Issue:8 Topics: Age Factors; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Health Expenditures; Health Resources; Humans; Imidazoles; Ipilimumab; Kaplan-Meier Estimate; Male; Markov Chains; Melanoma; Middle Aged; Models, Economic; Nivolumab; Oximes; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Sex Factors; Skin Neoplasms; Vemurafenib	2018
Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma. Oncology, 2018, Volume: 95, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Quality of Life; Radiation Dose Hypofractionation; Surveys and Questionnaires; Temozolomide	2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA oncology, 2019, 02-01, Volume: 5, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Dacarbazine; Disease Progression; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Nivolumab; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Treatment Outcome; Young Adult	2019
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. International journal of radiation oncology, biology, physics, 2013, Jun-01, Volume: 86, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therapy; Communication; Dacarbazine; Disease Progression; Fatigue; Female; Glioblastoma; Health Status; Humans; Karnofsky Performance Status; Male; Neuropsychological Tests; Prospective Studies; Quality of Life; Social Participation; Surveys and Questionnaires; Temozolomide	2013
Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. British journal of cancer, 2013, Jul-09, Volume: 109, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Ipilimumab; Melanoma; Neoplasm Staging; Survival Analysis	2013
Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. Anticancer research, 2013, Volume: 33, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Tamoxifen; Temozolomide; Treatment Outcome	2013
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer research, 2013, Volume: 33, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Survival Analysis; Temozolomide; Time Factors	2013
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. The oncologist, 2014, Volume: 19, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult	2014
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of neuro-oncology, 2014, Volume: 117, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Snake Venoms; Temozolomide; Treatment Outcome	2014
Whole brain reirradiation and concurrent temozolomide in patients with brain metastases. Journal of neuro-oncology, 2014, Volume: 118, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Retreatment; Retrospective Studies; Temozolomide; Treatment Outcome	2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA, 2014, Jun-18, Volume: 311, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Temozolomide; Treatment Outcome; Uveal Neoplasms	2014
Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. Neuro-oncology, 2015, Volume: 17, Issue:7 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Proportional Hazards Models; Temozolomide; Tumor Suppressor Proteins	2015
Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Dacarbazine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prednisone; Procarbazine; Prospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vincristine; Young Adult	2015
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. Cancer immunology, immunotherapy : CII, 2015, Volume: 64, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; WT1 Proteins	2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. The New England journal of medicine, 2015, Apr-23, Volume: 372, Issue:17 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Proportional Hazards Models; Recurrence; Survival Analysis; Vinblastine; Young Adult	2015
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jul-01, Volume: 33, Issue:19 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Double-Blind Method; Female; Glioblastoma; Humans; Male; Middle Aged; Placebos; Quality of Life; Surveys and Questionnaires; Survival Analysis; Temozolomide	2015
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. International journal of radiation oncology, biology, physics, 2015, Aug-01, Volume: 92, Issue:5 Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide; Time Factors; Valproic Acid	2015
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5 Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; CTLA-4 Antigen; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; Endocrine System Diseases; Female; Humans; Immunosuppressive Agents; Ipilimumab; Japan; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melanoma; Middle Aged; Neoplasm Proteins; Remission Induction; Treatment Outcome	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Electric Stimulation Therapy; Europe; Female; Glioblastoma; Humans; Israel; Maintenance Chemotherapy; Male; Middle Aged; Republic of Korea; Temozolomide; United States; Young Adult	2015
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma]. Zhonghua yi xue za zhi, 2015, Aug-18, Volume: 95, Issue:31 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Prognosis; Promoter Regions, Genetic; Radiotherapy, Intensity-Modulated; Remission Induction; Survival Rate; Temozolomide; Tumor Suppressor Proteins	2015
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-oncology, 2016, Volume: 18, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult	2016
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Apr-20, Volume: 34, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infant; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Tablets; Temozolomide; Time Factors; Treatment Outcome; United States; Young Adult	2016
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. Journal of neuro-oncology, 2016, Volume: 128, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Procarbazine; Snake Venoms; Temozolomide; Treatment Failure; Tumor Suppressor Proteins; Young Adult	2016
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Cancer medicine, 2016, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Dacarbazine; Disease Progression; Drug Substitution; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Middle Aged; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Survival Analysis	2016
[No general recommendation for waiving consolidated radiotherapy in Hodgkin lymphoma and negative PET results after completion of chemotherapy]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2016, Volume: 192, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prevalence; Proportional Hazards Models; Recurrence; Survival Analysis; Survival Rate; Treatment Outcome; United Kingdom; Vinblastine; Young Adult	2016
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro-oncology, 2016, Volume: 18, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide	2016
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro-oncology, 2017, 02-01, Volume: 19, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Neoplasm Grading; Prognosis; Prospective Studies; Survival Rate; Temozolomide; Young Adult	2017
Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. Medicine, 2017, Volume: 96, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; China; Cisplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome; Young Adult	2017
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. The New England journal of medicine, 2017, 03-16, Volume: 376, Issue:11 Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Quality of Life; Radiotherapy; Survival Analysis; Temozolomide	2017
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. International journal of radiation oncology, biology, physics, 2009, Feb-01, Volume: 73, Issue:2 Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Magnetic Resonance Imaging; Methionine; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retreatment; Software; Temozolomide; Treatment Failure; Young Adult	2009
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Radiotherapy; Temozolomide; Treatment Outcome	2008
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet. Oncology, 2009, Volume: 10, Issue:5 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Survival Analysis; Survival Rate; Temozolomide; Tumor Suppressor Proteins	2009
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. British journal of cancer, 2009, Apr-21, Volume: 100, Issue:8 Topics: Antineoplastic Agents; Biopsy; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; DNA Replication; DNA, Neoplasm; Humans; Kinetics; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Purines; Temozolomide	2009
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Isotretinoin; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome	2009
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. International journal of radiation oncology, biology, physics, 2010, May-01, Volume: 77, Issue:1 Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Glioma; Humans; Male; Pons; Prospective Studies; Temozolomide	2010
Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study. Journal of neuro-oncology, 2010, Volume: 97, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Conformal; Temozolomide; Treatment Outcome	2010
Population-based study of pseudoprogression after chemoradiotherapy in GBM. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2009, Volume: 36, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Community Health Planning; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome	2009
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-10, Volume: 27, Issue:35 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Glioma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Lomustine; Male; Middle Aged; Mutation; Procarbazine; Promoter Regions, Genetic; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Temozolomide; Time Factors; Treatment Failure; Tumor Suppressor Proteins; Vincristine; Young Adult	2009
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Archives of neurology, 2010, Volume: 67, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibroblast Growth Factor 1; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Oligopeptides; Receptor, TIE-1; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Treatment Outcome	2010
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-20, Volume: 28, Issue:12 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Radiotherapy, Adjuvant; Recurrence; Temozolomide; Time Factors; Treatment Outcome	2010
A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma research, 2010, Volume: 20, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 9; Melanoma; Middle Aged; Patient Compliance; Prognosis; Recombinant Proteins; Survival Rate; Vascular Endothelial Growth Factor A	2010
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1 Topics: Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease Progression; Female; Humans; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2011
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel	2011
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. Journal of neuro-oncology, 2011, Volume: 103, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Temozolomide; Treatment Outcome; Young Adult	2011
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-01, Volume: 29, Issue:19 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; North America; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Temozolomide; Vascular Endothelial Growth Factor A	2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England journal of medicine, 2011, Jun-30, Volume: 364, Issue:26 Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Double-Blind Method; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Liver Function Tests; Male; Melanoma; Middle Aged; Proportional Hazards Models	2011
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial. Melanoma research, 2011, Volume: 21, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choice Behavior; Cooperative Behavior; Cyclophosphamide; Dacarbazine; Dermatology; Disease Progression; Female; Humans; Interdisciplinary Communication; Male; Medical Oncology; Melanoma; Middle Aged; Palliative Care; Patient Preference; Skin Neoplasms; Societies, Medical; Vincristine	2011
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer, 2012, Oct-01, Volume: 118, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Brain Neoplasms; Cohort Studies; Dacarbazine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Piperazines; Pyrimidines; Temozolomide; Thrombocytopenia; Treatment Outcome	2012
ABVD vs. radiotherapy in early stage Hodgkin's lymphoma: A critical look at the NCIC HD.6 trial. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2012, Volume: 188, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Chemoradiotherapy; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Doxorubicin; Hodgkin Disease; Humans; Lymphatic Irradiation; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Risk Factors; United States; Vinblastine	2012
The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. Journal of medical imaging and radiation oncology, 2012, Volume: 56, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Incidence; Male; Middle Aged; Radiotherapy, Conformal; Risk Factors; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome; Victoria	2012
Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma. Cancer science, 2013, Volume: 104, Issue:2 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Immunotherapy, Active; Male; Middle Aged; Nimustine; Temozolomide	2013
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. Journal of neuro-oncology, 2013, Volume: 112, Issue:2 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide	2013
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme. British journal of cancer, 2003, Feb-24, Volume: 88, Issue:4 Topics: Adolescent; Adult; Aged; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Survival Rate	2003
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:4 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Procarbazine; Temozolomide; Treatment Outcome; Vincristine	2003
Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial. Melanoma research, 2003, Volume: 13, Issue:2 Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lomustine; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Tamoxifen; Time Factors; Treatment Outcome; Vinblastine	2003
Biochemotherapy for metastatic melanoma with limited central nervous system involvement. Oncology, 2003, Volume: 64, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Radiosurgery; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vinblastine	2003
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jun-15, Volume: 21, Issue:12 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Female; Glioma; Humans; Isotretinoin; Male; Middle Aged; Neoplasm Recurrence, Local; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome	2003
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-01, Volume: 21, Issue:13 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Temozolomide; Treatment Outcome	2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-01, Volume: 21, Issue:13 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Survival; Temozolomide; Thalidomide	2003
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymph Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-01, Volume: 21, Issue:19 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Disease Progression; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Prognosis; Radiotherapy; Recurrence; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine	2003
A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. International journal of clinical oncology, 2003, Volume: 8, Issue:5 Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Survival Rate; Temozolomide	2003
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:12 Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Seizures; Temozolomide; Treatment Outcome	2003
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:12 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Quality of Life; Radiography; Seizures; Temozolomide; Treatment Outcome	2003
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ondansetron; Temozolomide	2004
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. Journal of neuro-oncology, 2004, Volume: 66, Issue:1-2 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood; Brain Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide	2004
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Onco Cancer, 2004, Apr-15, Volume: 100, Issue:8 Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; BCG Vaccine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Treatment Outcome	2004
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer, 2004, Apr-15, Volume: 100, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide	2004
Temozolomide for treatment-resistant recurrent meningioma. Neurology, 2004, Apr-13, Volume: 62, Issue:7 Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Treatment Outcome	2004
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2004, Volume: 11, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome	2004
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology, 2004, Jun-08, Volume: 62, Issue:11 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gastrointestinal Diseases; Glioblastoma; Hematologic Diseases; Humans; Male; Middle Aged; Prospective Studies; Remission Induction; Salvage Therapy; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome	2004
ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Disease Progression; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiotherapy; Remission Induction; Time Factors; Treatment Outcome; Vinblastine	2004
Temozolomide in paediatric high-grade glioma: a key for combination therapy? British journal of cancer, 2004, Aug-02, Volume: 91, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Temozolomide; Treatment Outcome	2004
Initial chemotherapy in gliomatosis cerebri. Neurology, 2004, Jul-27, Volume: 63, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Karnofsky Performance Status; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Neuroepithelial; Oligodendroglioma; Procarbazine; Survival Analysis; Temozolomide; Treatment Outcome; Vincristine	2004
Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. Neurology, 2004, Jul-27, Volume: 63, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Life Tables; Male; Middle Aged; Neoplasms, Neuroepithelial; Oligodendroglioma; Prospective Studies; Temozolomide; Treatment Outcome	2004
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology, 2004, Aug-10, Volume: 63, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cohort Studies; Combined Modality Therapy; Contrast Media; Cranial Irradiation; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease Progression; Female; Follow-Up Studies; Gadolinium; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Patient Selection; Procarbazine; Temozolomide; Vincristine	2004
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma research, 2004, Volume: 14, Issue:4 Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide; Time Factors	2004
Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Recurrence; Treatment Outcome; Vinblastine	2004
Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. Ideggyogyaszati szemle, 2004, Nov-20, Volume: 57, Issue:11-12 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome	2004
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine, 2005, Mar-10, Volume: 352, Issue:10 Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Computer-Assisted; Survival Analysis; Temozolomide	2005
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide	2005
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. Journal of neuro-oncology, 2006, Volume: 76, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Stereotaxic Techniques; Survival Analysis; Temozolomide; Treatment Outcome	2006
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioma; Guanine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Temozolomide	2005
A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma. American journal of clinical oncology, 2005, Volume: 28, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Temozolomide	2005
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 1 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Approval; Female; Glioblastoma; Humans; Male; Middle Aged; Pneumocystis; Pneumocystis Infections; Proportional Hazards Models; Quality of Life; Radiotherapy; Salvage Therapy; Temozolomide; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration	2005
Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. International journal of radiation oncology, biology, physics, 2006, Mar-01, Volume: 64, Issue:3 Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Temozolomide	2006
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-10, Volume: 23, Issue:35 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Survival Analysis; Temozolomide; Treatment Outcome	2005
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Prednisolone; Procarbazine; Treatment Outcome; Vinblastine; Vincristine	2005
Surgery, radiotherapy and temozolomide in treating high-grade gliomas. Frontiers in bioscience : a journal and virtual library, 2006, May-01, Volume: 11 Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Quality of Life; Radiotherapy; Temozolomide; Time Factors; Treatment Outcome	2006
Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. Acta neurochirurgica, 2006, Volume: 148, Issue:2 Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Child; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Spinal Cord; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome	2006
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Patient Selection; Temozolomide; Treatment Outcome	2006
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol. BMC cancer, 2006, May-18, Volume: 6 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cetuximab; Combined Modality Therapy; Dacarbazine; Disease Progression; ErbB Receptors; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide	2006
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2 Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aspartate Aminotransferases; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Ifosfamide; Infusions, Intravenous; Liver; Lung; Male; Middle Aged; Remission Induction; Sarcoma; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome	2007
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. Journal of cancer research and clinical oncology, 2006, Volume: 132, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Outcome	2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-10, Volume: 24, Issue:29 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Survival Analysis; Thionucleotides; Treatment Outcome	2006
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). British journal of cancer, 2006, Nov-06, Volume: 95, Issue:9 Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; Disease Progression; DNA Methylation; Drug Administration Schedule; Female; Glioblastoma; Humans; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide; Treatment Outcome	2006
Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Disease Progression; Doxorubicin; Female; Germany; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Prognosis; Radiation Injuries; Survival Rate; Treatment Outcome; Vinblastine; Vincristine	2007
MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Annals of neurology, 2006, Volume: 60, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair Enzymes; Female; Genetic Markers; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Survival Rate; Temozolomide; Tumor Suppressor Protein p14ARF; Tumor Suppressor Proteins	2006
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-20, Volume: 25, Issue:18 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Enzyme Inhibitors; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Purines; Skin Neoplasms; Temozolomide; Treatment Outcome	2007
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. Cancer biology & therapy, 2007, Volume: 6, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Temozolomide; Thalidomide; Treatment Outcome	2007
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Prospective Studies; Survival Analysis; Temozolomide; Treatment Outcome	2007
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Treatment Outcome; Vinblastine	2007
Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Neoplasm Staging; Treatment Outcome; Vinblastine	2007
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surgical neurology, 2008, Volume: 70, Issue:3 Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Monoterpenes; Neoplasm Recurrence, Local; Oncogene Protein p21(ras); Signal Transduction; Survival Rate; Temozolomide; Transforming Growth Factor beta; Treatment Outcome	2008
A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. British journal of cancer, 2008, May-20, Volume: 98, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dacarbazine; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Staging; Purines; Temozolomide; Treatment Failure	2008
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. Leukemia & lymphoma, 1995, Volume: 16, Issue:5-6 Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4 Lymphocyte Count; Cohort Studies; Combined Modality Therapy; Comorbidity; Dacarbazine; Disease Progression; Doxorubicin; Female; France; Herpesviridae Infections; Herpesvirus 4, Human; HIV Infections; Hodgkin Disease; Homosexuality, Male; Humans; Life Tables; Lymphoma, AIDS-Related; Male; Mechlorethamine; Middle Aged; Prednisone; Procarbazine; Radioisotope Teletherapy; Registries; Remission Induction; Risk Factors; Substance Abuse, Intravenous; Survival Analysis; Tumor Virus Infections; Vinblastine; Vincristine	1995
Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Gynecologic oncology, 1996, Volume: 61, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Etoposide; Female; Humans; Hydroxyurea; Middle Aged; Mixed Tumor, Mesodermal; Neoplasm Recurrence, Local; Treatment Outcome; Uterine Neoplasms	1996
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. Melanoma research, 1998, Volume: 8, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Damage; Glutathione Transferase; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Leukocytes, Mononuclear; Melanoma; Neoplasm Staging; Polymerase Chain Reaction; Recombinant Proteins; Skin Neoplasms; Vinblastine	1998
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9 Suppl 5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Prednisone; Procarbazine; Survival Rate; Treatment Outcome; Vinblastine; Vincristine	1998
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer, 1999, May-01, Volume: 85, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Survival Rate; Tamoxifen; Treatment Outcome	1999
Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. Journal of cancer research and clinical oncology, 1999, Volume: 125, Issue:7 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Ifosfamide; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome	1999
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. British journal of cancer, 2000, Volume: 82, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome	2000
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioblastoma; Health Status; Humans; Male; Middle Aged; Procarbazine; Quality of Life; Temozolomide	2000
Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma. Melanoma research, 2000, Volume: 10, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Safety; Survival Analysis; Thymalfasin; Thymosin; Treatment Outcome	2000
A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:6 Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Temozolomide	2000
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:14 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Survival Analysis; Temozolomide; Treatment Failure	2000
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Temozolomide	2001
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncology, 2001, Volume: 3, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Implants; Drug Synergism; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Safety; Supratentorial Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome	2001
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. Journal of neuro-oncology, 2001, Volume: 53, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Disease Progression; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Tomography, X-Ray Computed	2001
Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. American journal of surgery, 2002, Volume: 183, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Epirubicin; Female; Hemodynamics; Humans; Hypoxia; Leg; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Pelvis; Skin Neoplasms; Treatment Outcome	2002
A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer, 2002, Jan-15, Volume: 94, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Interferon-alpha; Interleukin-2; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine	2002
Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study. Medical oncology (Northwood, London, England), 2001, Volume: 18, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Neutropenia; Salvage Therapy; Skin Neoplasms; Thrombocytopenia; Treatment Outcome; Vinblastine	2001
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2002

Other Studies

178 other study(ies) available for dacarbazine and Disease Exacerbation

Article	Year
Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma. Japanese journal of clinical oncology, 2022, Oct-06, Volume: 52, Issue:10 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; DNA; Glioblastoma; Humans; Isocitrate Dehydrogenase; Methyltransferases; Temozolomide	2022
Cardiovascular and Thyroid Late Effects in Pediatric Patients With Hodgkin Lymphoma Treated With ABVD Protocol. Journal of pediatric hematology/oncology, 2023, 05-01, Volume: 45, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cardiotoxicity; Child; Child, Preschool; Cross-Sectional Studies; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Hypertension; Vinblastine	2023
Cardiovascular and Thyroid Late Effects in Pediatric Patients With Hodgkin Lymphoma Treated With ABVD Protocol: Erratum. Journal of pediatric hematology/oncology, 2023, Jul-01, Volume: 45, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Neoplasm Staging; Thyroid Gland; Vinblastine	2023
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report. Current problems in cancer, 2021, Volume: 45, Issue:6 Topics: Adenosine Monophosphate; Adult; Alanine; Amides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brentuximab Vedotin; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Male; Pregnenediones; Pyrazines; Time Factors; Vinblastine	2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 07-10, Volume: 39, Issue:20 Topics: Adolescent; Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Chemoradiotherapy; Dacarbazine; Disease Progression; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Progression-Free Survival; Risk Assessment; Risk Factors; Time Factors; United States; Vinblastine; Young Adult	2021
Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; France; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Polymerase Chain Reaction; Precision Medicine; Predictive Value of Tests; Promoter Regions, Genetic; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins	2017
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-oncology, 2017, Aug-01, Volume: 19, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Tumor Suppressor Proteins	2017
SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma. Oncotarget, 2017, Jul-04, Volume: 8, Issue:27 Topics: Adult; Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Dacarbazine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; RNA, Small Nucleolar; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays	2017
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling. Experimental cell research, 2017, 08-01, Volume: 357, Issue:1 Topics: Animals; beta-Arrestin 1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Progression; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Neoplasm Invasiveness; Proto-Oncogene Proteins pp60(c-src); Signal Transduction; Temozolomide	2017
TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT. African journal of traditional, complementary, and alternative medicines : AJTCAM, 2016, Volume: 13, Issue:6 Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Phytotherapy; Plant Preparations; Plants, Medicinal; Temozolomide; Treatment Outcome	2016
Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy. Journal of neuro-oncology, 2017, Volume: 134, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Proportional Hazards Models; Temozolomide	2017
High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas. World neurosurgery, 2017, Volume: 105 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Glypicans; Humans; Isocitrate Dehydrogenase; Karnofsky Performance Status; Ki-67 Antigen; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins	2017
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas, 2017, Volume: 46, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Child; Dacarbazine; Databases, Factual; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Pharmacogenetics; Promoter Regions, Genetic; Sequence Analysis, DNA; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Young Adult	2017
Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma. PloS one, 2017, Volume: 12, Issue:7 Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Perfusion; Spin Labels; Temozolomide	2017
Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone? British journal of haematology, 2017, Volume: 179, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Patient Selection; Positron Emission Tomography Computed Tomography; Radiotherapy; Radiotherapy Dosage; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Treatment Outcome; Vinblastine; Young Adult	2017
[Contribution of temozolomide chemotherapy for intramedullary grade II spinal cord astrocytomas in adults: Our experience]. Neuro-Chirurgie, 2017, Volume: 63, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Spinal Cord Neoplasms; Temozolomide; Young Adult	2017
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma. The Journal of pathology, 2017, Volume: 243, Issue:4 Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Gene Expression Regulation, Neoplastic; Glioma; GPI-Linked Proteins; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplastic Stem Cells; Signal Transduction; Temozolomide; Time Factors; Tumor Cells, Cultured; Tumor Microenvironment	2017
Sequential proton boost after standard chemoradiation for high-grade glioma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017, Volume: 125, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Proton Therapy; Retrospective Studies; Temozolomide; Young Adult	2017
Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Che AJNR. American journal of neuroradiology, 2017, Volume: 38, Issue:12 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Reproducibility of Results; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Temozolomide	2017
Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy. Neuroradiology, 2018, Volume: 60, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity; Temozolomide	2018
Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series. PloS one, 2017, Volume: 12, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Disease Progression; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Temozolomide; Treatment Failure; Vascular Endothelial Growth Factor A; Young Adult	2017
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors. Journal of pharmaceutical sciences, 2018, Volume: 107, Issue:3 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Hydrogels; Injections; Iodine Radioisotopes; Male; Mice; Mice, Nude; Prognosis; Temozolomide	2018
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PloS one, 2017, Volume: 12, Issue:12 Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Bridged-Ring Compounds; Cell Proliferation; Cell Survival; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Janus Kinase 2; Male; Mice; Mice, SCID; Microsomes, Liver; Permeability; Pyrimidines; STAT3 Transcription Factor; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays	2017
Inflammatory Cytokine Pattern Is Sex-Dependent in Mouse Cutaneous Melanoma Experimental Model. Journal of immunology research, 2017, Volume: 2017 Topics: Animals; Antineoplastic Agents, Alkylating; Carcinogenesis; Cytokines; Dacarbazine; Disease Models, Animal; Disease Progression; Female; Humans; Inflammation Mediators; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Sex; Skin Neoplasms	2017
Reversing effect of Lupeol on vasculogenic mimicry in murine melanoma progression. Microvascular research, 2019, Volume: 121 Topics: AC133 Antigen; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Biological Mimicry; Cadherins; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Endothelial Progenitor Cells; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Neovascularization, Pathologic; Pentacyclic Triterpenes; Phenotype; Platelet Endothelial Cell Adhesion Molecule-1; Tumor Burden	2019
Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression. Journal of neuro-oncology, 2013, Volume: 112, Issue:3 Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Radiometry; Radiotherapy; Temozolomide	2013
Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14 Topics: Antidiuretic Hormone Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Doxorubicin; Gemcitabine; Humans; Hyponatremia; Ifosfamide; Immunohistochemistry; Immunophenotyping; Inappropriate ADH Syndrome; Juxtaglomerular Apparatus; Kidney Neoplasms; Luminescent Measurements; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Paraneoplastic Syndromes; Renin; Tolvaptan; Vinblastine; Vinorelbine	2013
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2013, Volume: 29, Issue:7 Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult	2013
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV. PloS one, 2013, Volume: 8, Issue:5 Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell Survival; Dacarbazine; Disease Progression; Extracellular Matrix; Fibronectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Glioma; Humans; Integrin alphaV; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Oligopeptides; Proteomics; Reproducibility of Results; RNA, Messenger; Spheroids, Cellular; Survival Analysis; Temozolomide	2013
Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Radiology, 2013, Volume: 269, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome	2013
The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis. PloS one, 2013, Volume: 8, Issue:10 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jumonji Domain-Containing Histone Demethylases; Male; Melanoma; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Staging; Neoplasm Transplantation; Neoplastic Stem Cells; Nuclear Proteins; Repressor Proteins; Side-Population Cells; Skin Neoplasms; Tumor Burden	2013
Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. Journal of neuro-oncology, 2014, Volume: 116, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Tumor Suppressor Proteins	2014
Is there pseudoprogression in secondary glioblastomas? International journal of radiation oncology, biology, physics, 2013, Dec-01, Volume: 87, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chromosomes, Human, 1-3; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Deletion; Glioblastoma; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins	2013
An absolute obstacle: cardiac metastasis of synovial sarcoma. The American journal of medicine, 2014, Volume: 127, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Heart Atria; Heart Neoplasms; Humans; Ifosfamide; Male; Polyethylene Glycols; Sarcoma, Synovial; Shoulder; Treatment Failure; Treatment Refusal; Vascular Neoplasms; Vena Cava, Superior	2014
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice. International journal of dermatology, 2014, Volume: 53, Issue:11 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Community Health Services; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Platinum Compounds; Practice Patterns, Physicians'; Retrospective Studies; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome	2014
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. BMC complementary and alternative medicine, 2014, Mar-30, Volume: 14 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Disease Progression; Drugs, Chinese Herbal; Female; Glioblastoma; Herb-Drug Interactions; Humans; Irinotecan; Liver; Middle Aged; Phytotherapy; Temozolomide	2014
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy. International journal of radiation oncology, biology, physics, 2014, Sep-01, Volume: 90, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Choline; Contrast Media; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gadolinium; Glioblastoma; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Matched-Pair Analysis; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy Dosage; Temozolomide; Time Factors	2014
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme. Targeted oncology, 2014, Volume: 9, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Fatal Outcome; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Pineal Gland; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome	2014
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2014, Volume: 21, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide; Young Adult	2014
Clinicopathological and molecular features of malignant optic pathway glioma in an adult. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioma; Humans; Isocitrate Dehydrogenase; Middle Aged; Optic Nerve Glioma; Radiosurgery; Temozolomide; Vision Disorders; Visual Fields	2015
ADC texture--an imaging biomarker for high-grade glioma? Medical physics, 2014, Volume: 41, Issue:10 Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Follow-Up Studies; Glioma; Humans; Image Interpretation, Computer-Assisted; Middle Aged; Multivariate Analysis; Neoplasm Grading; Principal Component Analysis; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome	2014
Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. Radiology, 2015, Volume: 274, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Temozolomide; Treatment Outcome	2015
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell death & disease, 2014, Oct-30, Volume: 5 Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Female; Glioma; Glutathione; Humans; Mice, Nude; Temozolomide; Tumor Suppressor Protein p53	2014
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis. Oncotarget, 2014, Nov-30, Volume: 5, Issue:22 Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Disease Progression; Down-Regulation; Female; Glioma; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Prognosis; Repressor Proteins; RNA, Small Interfering; Temozolomide; Transcription Factors; Treatment Outcome; Veratrum Alkaloids; Zinc Finger Protein GLI1	2014
Primary glioblastoma of the trigeminal nerve root entry zone: case report. Journal of neurosurgery, 2015, Volume: 122, Issue:1 Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Combined Modality Therapy; Cranial Nerve Neoplasms; Dacarbazine; Disease Progression; Glioblastoma; Humans; Male; Temozolomide; Trigeminal Nerve Diseases	2015
Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? Journal of chemotherapy (Florence, Italy), 2015, Volume: 27, Issue:2 Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Hospitals, Religious; Hospitals, University; Humans; Male; Neoplasm Grading; Neurons; Prognosis; Prospective Studies; Rome; Survival Analysis; Temozolomide	2015
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR. American journal of neuroradiology, 2015, Volume: 36, Issue:5 Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Retrospective Studies; Temozolomide	2015
Outcome of salvage treatment for recurrent glioblastoma. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiosurgery; Reoperation; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome	2015
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta neuropathologica, 2015, Volume: 129, Issue:4 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA Repair-Deficiency Disorders; Female; Glioma; Humans; Male; Mutation; Receptors, Immunologic; Statistics, Nonparametric; Temozolomide; Tumor Suppressor Proteins	2015
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:5 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human; Cyclin-Dependent Kinase 4; Dacarbazine; Disease Progression; Fatal Outcome; Female; Genetic Association Studies; Genetic Predisposition to Disease; Glioblastoma; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Temozolomide; Time Factors; Treatment Outcome	2015
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proceedings of the National Academy of Sciences of the United States of America, 2015, Mar-17, Volume: 112, Issue:11 Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Gene Amplification; Gene Expression Regulation, Neoplastic; Genome, Human; Glioma; Humans; Isoenzymes; Mice; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Signal Transduction; Temozolomide; Transcription, Genetic	2015
Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression. PloS one, 2015, Volume: 10, Issue:3 Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Dacarbazine; Disease Progression; Drug Therapy, Combination; Male; Melanoma; Mice; Skin Neoplasms	2015
[Radiation and temozolomide therapy]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2 Topics: Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Risk Factors; Temozolomide	2015
Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2015, Volume: 19, Issue:3 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Damage, Chronic; Cell Dedifferentiation; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease Progression; Female; Frontal Lobe; Glioma; Hippocampus; Humans; Neoplasm Recurrence, Local; Organ Sparing Treatments; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Supratentorial Neoplasms; Temozolomide; Tumor Burden; Young Adult	2015
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. Oncotarget, 2015, May-10, Volume: 6, Issue:13 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine CXCL12; Chemoradiotherapy; Child; Child, Preschool; Cyclams; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Gene Expression Profiling; Glioblastoma; Heterocyclic Compounds; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Receptors, CXCR4; Retrospective Studies; Signal Transduction; Temozolomide; Time Factors; Tissue Culture Techniques; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult	2015
An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2015, Volume: 116, Issue:3 Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Mice, SCID; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Image-Guided; Spheroids, Cellular; Temozolomide	2015
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. Anticancer research, 2015, Volume: 35, Issue:9 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Female; Glioma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Temozolomide; Time Factors; Tumor Burden	2015
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. Journal of neuro-oncology, 2015, Volume: 125, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Alkylating; Brain Neoplasms; Contrast Media; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; ROC Curve; Temozolomide; Time Factors; Treatment Outcome	2015
Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. AJNR. American journal of neuroradiology, 2015, Volume: 36, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Ependyma; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Sensitivity and Specificity; Temozolomide; Young Adult	2015
Metformin influences progression in diabetic glioblastoma patients. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2015, Volume: 191, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Glucose; Brain; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Diabetes Complications; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Hyperglycemia; Hypoglycemic Agents; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Retrospective Studies; Temozolomide; Young Adult	2015
Central nervous system Hodgkin lymphoma developing during systemic chemotherapy. British journal of haematology, 2016, Volume: 172, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; Dacarbazine; Disease Progression; Doxorubicin; Fatal Outcome; Hodgkin Disease; Humans; Magnetic Resonance Imaging; Male; Tomography, X-Ray Computed; Vinblastine	2016
[A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; China; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Doxorubicin; Hodgkin Disease; Humans; Multivariate Analysis; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Treatment Outcome; Vinblastine	2015
Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment. Pituitary, 2016, Volume: 19, Issue:2 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Humans; Hydrocortisone; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Temozolomide; Treatment Failure	2016
Advanced Lymphocyte-rich Classical Hodgkin Lymphoma Complicated with Fatal Hemophagocytic Syndrome. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Neoplasms; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Lymphatic Metastasis; Lymphocytes; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Vinblastine	2016
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression. Oncotarget, 2016, Mar-22, Volume: 7, Issue:12 Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Humans; Male; Mice; Mice, Nude; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2016
Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma. PloS one, 2016, Volume: 11, Issue:3 Topics: Biomarkers, Tumor; Dacarbazine; Disease Progression; DNA Methylation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Matrix Metalloproteinase 9; Neoplasm Grading; Prognosis; Proportional Hazards Models; RNA, Messenger; Survival Analysis; Temozolomide; Treatment Outcome	2016
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. Journal of neuro-oncology, 2016, Volume: 129, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Histones; Humans; Infant; Male; Radiotherapy; Risk Factors; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult	2016
Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma. Neurology, 2016, 07-05, Volume: 87, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Oligodendroglioma; Temozolomide	2016
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Cancer research and treatment, 2017, Volume: 49, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult	2017
Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. Journal of neuro-oncology, 2016, Volume: 129, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Regression Analysis; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult	2016
Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence. Radiology, 2017, Volume: 282, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Cerebrovascular Circulation; Combined Modality Therapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Organometallic Compounds; Polymerase Chain Reaction; Retrospective Studies; Temozolomide; Treatment Outcome	2017
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. Oncotarget, 2016, Aug-30, Volume: 7, Issue:35 Topics: Animals; Antimalarials; Artemisinins; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Mice; Mice, Nude; Oxidative Stress; Physical Conditioning, Animal; Reactive Oxygen Species; Temozolomide	2016
Stem cell markers in glioma progression and recurrence. International journal of oncology, 2016, Volume: 49, Issue:5 Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Progression; Embryonic Stem Cells; Glioma; Humans; Immunoenzyme Techniques; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Octamer Transcription Factor-3; Prognosis; Proto-Oncogene Proteins c-myc; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Cells, Cultured	2016
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. The Lancet. Haematology, 2016, Volume: 3, Issue:10 Topics: Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bleomycin; Cohort Studies; Dacarbazine; Denmark; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Hodgkin Disease; Humans; Italy; Male; Multivariate Analysis; Poland; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Recurrence; Reed-Sternberg Cells; Retrospective Studies; STAT1 Transcription Factor; Treatment Failure; Tumor Microenvironment; Vinblastine	2016
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Clinical neurology and neurosurgery, 2016, Volume: 151 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins	2016
MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction. PloS one, 2016, Volume: 11, Issue:11 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Temozolomide; Young Adult	2016
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. Journal of neuro-oncology, 2017, Volume: 131, Issue:2 Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Dynamin III; Exosomes; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Temozolomide; Transcription Factor RelA	2017
Refractory pituitary adenoma: a novel classification for pituitary tumors. Oncotarget, 2016, Dec-13, Volume: 7, Issue:50 Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Cell Proliferation; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pituitary Neoplasms; Salvage Therapy; Temozolomide; Terminology as Topic; Time Factors; Treatment Outcome; Tumor Burden	2016
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. Fundamental & clinical pharmacology, 2017, Volume: 31, Issue:3 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Longitudinal Studies; Male; Models, Theoretical; Procarbazine; Temozolomide; Vincristine	2017
Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. International journal of radiation oncology, biology, physics, 2017, 02-01, Volume: 97, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Confidence Intervals; Dacarbazine; Disease Progression; Doxorubicin; Female; Fluorodeoxyglucose F18; Glycolysis; Hodgkin Disease; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Recurrence; Risk; Treatment Outcome; Tumor Burden; Vinblastine	2017
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy. Scientific reports, 2017, 02-08, Volume: 7 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Radiation; Female; Gamma Rays; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Survival Analysis; Temozolomide; Tumor Suppressor Proteins	2017
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications. Mathematical biosciences, 2017, Volume: 288 Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; Middle Aged; Models, Biological; Neoplasm Grading; Temozolomide	2017
[In vitro drug sensitivity profiling in melanoma]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2008, Volume: 6, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Humans; In Vitro Techniques; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Rate; Tumor Stem Cell Assay	2008
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Repair Enzymes; Fatal Outcome; Glioblastoma; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Remission Induction; Temozolomide	2008
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surgical neurology, 2009, Volume: 72, Issue:4 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Diagnostic Errors; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide	2009
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. Journal of neuro-oncology, 2009, Volume: 94, Issue:1 Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Odds Ratio; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide; Treatment Outcome	2009
Rechallenge with temozolomide in patients with recurrent gliomas. Journal of neurology, 2009, Volume: 256, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult	2009
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. Journal of cellular and molecular medicine, 2009, Volume: 13, Issue:9B Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cardenolides; Cell Line, Tumor; Dacarbazine; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Mice, Nude; Microscopy, Video; Neoplasm Metastasis; Neoplasm Transplantation; Sodium-Potassium-Exchanging ATPase; Temozolomide	2009
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clinical neurosurgery, 2008, Volume: 55 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; DNA Mismatch Repair; DNA Mutational Analysis; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Silencing; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Temozolomide	2008
[A case of sarcomatoid malignant peritoneal mesothelioma responding to combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine(CYVADIC)]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Disease Progression; Doxorubicin; Fatal Outcome; Female; Humans; Mesothelioma; Peritoneal Neoplasms; Sarcoma; Tomography, X-Ray Computed; Vincristine	2009
Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology, 2009, Volume: 90, Issue:1 Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Digestive System Neoplasms; Disease Progression; Endocrine Gland Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome	2009
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. Anticancer research, 2009, Volume: 29, Issue:7 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Tumor Suppressor Proteins	2009
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity. Anticancer research, 2009, Volume: 29, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Neoplasms, Neuroepithelial; Neovascularization, Pathologic; Prognosis; Pyrazoles; Sulfonamides; Survival Rate; Temozolomide; Vascular Endothelial Growth Factor A	2009
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurgical review, 2010, Volume: 33, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazine; Databases, Factual; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Kinetics; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Oligodendroglioma; Retrospective Studies; Temozolomide; Young Adult	2010
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Annals of clinical and laboratory science, 2009,Fall, Volume: 39, Issue:4 Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Middle Aged; Myelodysplastic Syndromes; Skin; Temozolomide	2009
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. Melanoma research, 2010, Volume: 20, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome	2010
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:8 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Recurrence; Temozolomide; Treatment Outcome; Young Adult	2010
Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:1 Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; Leiomyosarcoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Recurrence; Retrospective Studies; Temozolomide; Uterine Neoplasms	2010
Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2010, Volume: 37, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome	2010
Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Safety; Survival Rate; Temozolomide; Young Adult	2010
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-20, Volume: 28, Issue:12 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Glioma; Humans; Radiotherapy, Adjuvant; Recurrence; Temozolomide; Time Factors; Treatment Outcome	2010
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. International journal of radiation oncology, biology, physics, 2011, Jan-01, Volume: 79, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Radiotherapy Planning, Computer-Assisted; Temozolomide; Tomography, X-Ray Computed; Treatment Failure; Tumor Burden; Young Adult	2011
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Neuro-oncology, 2010, Volume: 12, Issue:9 Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diffusion Tensor Imaging; Disease Progression; Disease-Free Survival; Glioblastoma; Humans; Prognosis; Radiotherapy; Temozolomide	2010
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. Journal of neuro-oncology, 2011, Volume: 102, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Immunoenzyme Techniques; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult	2011
A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. Journal of neuro-oncology, 2011, Volume: 102, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Quality of Life; Survival Rate; Temozolomide; Treatment Outcome	2011
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors. Journal of neuro-oncology, 2011, Volume: 103, Issue:1 Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome	2011
Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide. Anti-cancer drugs, 2010, Volume: 21, Issue:10 Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Cervical Vertebrae; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Fatal Outcome; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Neurosurgical Procedures; Radiotherapy; Spinal Cord Neoplasms; Temozolomide	2010
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. Journal of neuro-oncology, 2011, Volume: 103, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide	2011
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma. Cancer biology & therapy, 2010, Dec-01, Volume: 10, Issue:11 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interleukin-2; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Temozolomide; Treatment Outcome	2010
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro-oncology, 2011, Volume: 13, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Perfusion; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Treatment Outcome	2011
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro-oncology, 2011, Volume: 13, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; Female; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Molecular Probe Techniques; Nucleic Acid Amplification Techniques; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome	2011
[Efficiency of radiation or chemoradiation therapy for diffusely growing brainstem tumors in children]. Vestnik rentgenologii i radiologii, 2008, Issue:2-3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Dacarbazine; Disease Progression; Humans; Temozolomide; Treatment Outcome; Vincristine	2008
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer, 2011, Oct-15, Volume: 117, Issue:20 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins	2011
[Nephropathy following administration of angiogenesis inhibitors]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2011, Volume: 31, Issue:2 Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bowman Capsule; Dacarbazine; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Endothelium, Vascular; Fibrosarcoma; Gemcitabine; Glomerulonephritis, Membranoproliferative; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Muscle Neoplasms; Podocytes; Proteinuria; Taxoids; Vascular Endothelial Growth Factor A	2011
Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques. Fukuoka igaku zasshi = Hukuoka acta medica, 2010, Volume: 101, Issue:12 Topics: Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Middle Aged; Positron-Emission Tomography; Temozolomide	2010
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. International journal of radiation oncology, biology, physics, 2012, Apr-01, Volume: 82, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Radiosurgery; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Failure; Vascular Endothelial Growth Factor A; Young Adult	2012
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. Anticancer research, 2011, Volume: 31, Issue:3 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Ependymoma; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Recurrence; Supratentorial Neoplasms; Temozolomide; Treatment Outcome	2011
Response to nimotuzumab in a child with a progressive diffuse intrinsic pontine glioma. Pediatrics international : official journal of the Japan Pediatric Society, 2011, Volume: 53, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Dacarbazine; Disease Progression; ErbB Receptors; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Pons; Temozolomide	2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncology, 2011, Volume: 13, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, Human, Pair 1; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; International Agencies; Lomustine; Male; Middle Aged; Oligodendroglioma; Procarbazine; Radiotherapy; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Vincristine; Young Adult	2011
Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions. The Journal of investigative dermatology, 2011, Volume: 131, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Disease Progression; Extracellular Matrix; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Kaplan-Meier Estimate; Lymphocytes; Male; Melanoma; Middle Aged; Osteonectin; Skin Neoplasms; Stromal Cells; Tumor Microenvironment; Young Adult	2011
Glioblastoma: patterns of recurrence and efficacy of salvage treatments. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2011, Volume: 38, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Tomography, X-Ray Computed	2011
Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. Journal of neuro-oncology, 2012, Volume: 106, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Glioblastoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide	2012
In regard McDonald et al., to Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma (Int J Radiat Oncol Biol Phys 2011;79:130-136). International journal of radiation oncology, biology, physics, 2011, Sep-01, Volume: 81, Issue:1 Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Planning, Computer-Assisted; Temozolomide; Treatment Failure; Tumor Burden	2011
Chemotherapy: Advanced Hodgkin lymphoma--balancing toxicity and cure. Nature reviews. Clinical oncology, 2011, Sep-06, Volume: 8, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dacarbazine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Induction Chemotherapy; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Treatment Outcome; Vinblastine; Vincristine	2011
Conditional probability of survival in patients with newly diagnosed glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-01, Volume: 29, Issue:31 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Factors; Temozolomide	2011
Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence! Nature reviews. Clinical oncology, 2011, Oct-04, Volume: 8, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Salvage Therapy; Treatment Outcome; Vinblastine; Vincristine	2011
Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation. Radiation oncology (London, England), 2011, Oct-21, Volume: 6 Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Risk; Temozolomide; Time Factors; Treatment Outcome	2011
Prolonged administration of temozolomide in adult patients with anaplastic glioma. Anticancer research, 2011, Volume: 31, Issue:11 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Time Factors	2011
[The usefulness of neo- and adjuvant therapy in the treatment of cutaneous melanoma]. Voprosy onkologii, 2011, Volume: 57, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Radiotherapy, Adjuvant; Retrospective Studies; Skin Neoplasms; Surgical Procedures, Operative; Treatment Outcome; Vincristine	2011
Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:2 Topics: Aged; Antineoplastic Agents, Alkylating; Cell Hypoxia; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Oxygen; Positron-Emission Tomography; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome	2012
Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. Journal of neuro-oncology, 2012, Volume: 108, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult	2012
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anti-cancer drugs, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Compassionate Use Trials; Dacarbazine; Disease Progression; Glioma; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome	2012
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-20, Volume: 30, Issue:21 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Dacarbazine; Disease Progression; Fatal Outcome; Female; Gadolinium; Glioblastoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome	2012
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. Brain tumor pathology, 2013, Volume: 30, Issue:2 Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Mutation; Neoplasms, Multiple Primary; Oligodendroglioma; Radiotherapy; Retrospective Studies; Second-Look Surgery; Temozolomide	2013
A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 2012, Aug-23, Volume: 488, Issue:7412 Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Cell Tracking; Dacarbazine; Disease Models, Animal; Disease Progression; Female; Ganciclovir; Glioblastoma; Green Fluorescent Proteins; Male; Mice; Mice, Transgenic; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide; Transgenes	2012
Targeting neuroendocrine tumor: mixing standard options with novel therapies. Targeted oncology, 2012, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Indoles; Medical Oncology; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Temozolomide; Treatment Outcome	2012
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. TheScientificWorldJournal, 2012, Volume: 2012 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Disease Progression; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Temozolomide	2012
Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status. Journal of neuro-oncology, 2012, Volume: 110, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Grading; Prognosis; Quality of Life; Survival Rate; Temozolomide	2012
Radiation-induced spinal cord anaplastic astrocytoma subsequent to radiotherapy for testicular seminoma. Neurologia medico-chirurgica, 2012, Volume: 52, Issue:9 Topics: Antineoplastic Agents; Astrocytoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Fatal Outcome; Humans; Hydrocephalus; Laminectomy; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Nimustine; Seminoma; Spinal Cord Compression; Spinal Cord Neoplasms; Syringomyelia; Temozolomide; Testicular Neoplasms; Thoracic Vertebrae; Time Factors	2012
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors. Pathology, research and practice, 2012, Dec-15, Volume: 208, Issue:12 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; Disease Progression; Gliosarcoma; Humans; Isocitrate Dehydrogenase; Male; Mutation; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Oligodendroglioma; Temozolomide	2012
Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:1 Topics: Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Kaplan-Meier Estimate; Male; Melanoma; Temozolomide; Vincristine	2013
Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treate Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Transformation, Neoplastic; Child, Preschool; Dacarbazine; Dihydroxyphenylalanine; Disease Progression; Female; Fluorine Radioisotopes; Ganglioglioma; Humans; Magnetic Resonance Imaging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Temozolomide	2013
Combined temozolomide and radiation as an initial treatment for anaplastic glioma. Asia-Pacific journal of clinical oncology, 2013, Volume: 9, Issue:3 Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Supratentorial Neoplasms; Survival Rate; Temozolomide	2013
[Sarcoidosis-like reaction after treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in a patient with Hodgkin's lymphoma]. Medicina clinica, 2013, Aug-04, Volume: 141, Issue:3 Topics: Acute-Phase Proteins; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Diagnosis, Differential; Disease Progression; Doxorubicin; False Positive Reactions; Female; Granuloma; Hodgkin Disease; Humans; Lymphadenitis; Multimodal Imaging; Positron-Emission Tomography; Sarcoidosis; Sensitivity and Specificity; Tomography, X-Ray Computed; Vinblastine	2013
The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Journal of neuro-oncology, 2013, Volume: 112, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide; Tumor Suppressor Proteins	2013
Breast metastasis of anaplastic oligodendroglioma: a case report. Tumori, 2012, Volume: 98, Issue:6 Topics: Antineoplastic Agents, Alkylating; Aphasia; Brain Neoplasms; Breast Neoplasms, Male; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Mammography; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Temozolomide	2012
[Hodgkin's disease presenting with progressive liver failure]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2002, Volume: 43, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Liver Failure; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Neck; Thrombocytopenia; Treatment Outcome; Vinblastine	2002
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; CpG Islands; Dacarbazine; Disease Progression; DNA; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors	2003
Temozolomide: too early for definitive conclusions. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-01, Volume: 21, Issue:19 Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as Topic; Cognition Disorders; Dacarbazine; Disease Progression; Glioma; Humans; Radiation Injuries; Reproducibility of Results; Temozolomide	2003
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin. Neurology, 2003, Oct-14, Volume: 61, Issue:7 Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carboplatin; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Ependymoma; Gadolinium; Headache; Humans; Isotretinoin; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Remission Induction; Tamoxifen; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome	2003
Promises and controversies in the management of low-grade glioma. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:12 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Glioma; Humans; Neoplasm Staging; Prognosis; Temozolomide	2003
Gliomatosis cerebri: better definition, better treatment. Neurology, 2004, Jul-27, Volume: 63, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Astrocytoma; Brain; Brain Neoplasms; Cell Cycle Proteins; Dacarbazine; Disease Progression; Female; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Neuroepithelial; Nerve Tissue Proteins; Procarbazine; Temozolomide; Vincristine	2004
[Influence of age on treatment results in children and adolescents with Hodgkin's disease]. Przeglad lekarski, 2004, Volume: 61 Suppl 2 Topics: Adolescent; Age Distribution; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Radiation; Doxorubicin; Female; Hodgkin Disease; Humans; Logistic Models; Male; Multicenter Studies as Topic; Poland; Prednisone; Radiotherapy Dosage; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Time Factors; Vincristine	2004
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome. Neoplasma, 2005, Volume: 52, Issue:2 Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome	2005
Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: case report. Cancer investigation, 2005, Volume: 23, Issue:2 Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome	2005
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide	2005
Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Dacarbazine; Disease Progression; Doxorubicin; Follow-Up Studies; Hodgkin Disease; Humans; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome; Vinblastine; Vincristine	2005
[Favourable result for temozolomide in recurrent high-grade glioma]. Nederlands tijdschrift voor geneeskunde, 2005, Jun-18, Volume: 149, Issue:25 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome	2005
Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-01, Volume: 23, Issue:25 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Hodgkin Disease; Humans; Infant; Male; Recurrence; Retrospective Studies; Salvage Therapy; Vinblastine	2005
[Spinal and cerebral leptomeningeal seeding from a melanocytoma of the cerebello-pontine angle]. Wiener medizinische Wochenschrift (1946), 2005, Volume: 155, Issue:15-16 Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Arachnoid; Cerebellar Diseases; Cerebellar Neoplasms; Cerebellopontine Angle; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Disease Progression; Humans; Magnetic Resonance Imaging; Male; Melanocytes; Melanoma; Meningeal Neoplasms; Meninges; Neoplasm Recurrence, Local; Neoplasm Seeding; Pia Mater; Radiotherapy Dosage; Temozolomide; Time Factors	2005
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer, 2006, Apr-15, Volume: 106, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Disease Progression; DNA Repair; Female; Humans; Immunohistochemistry; Loss of Heterozygosity; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Oligodendroglioma; Temozolomide	2006
[Lymph node tuberculosis as primary manifestation of Hodgkin's disease]. Medizinische Klinik (Munich, Germany : 1983), 2006, Jun-15, Volume: 101, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Biopsy; Bleomycin; Dacarbazine; Diagnosis, Differential; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Lymph Nodes; Recurrence; Tomography, X-Ray Computed; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Vinblastine	2006
Implications of tissue transglutaminase expression in malignant melanoma. Molecular cancer therapeutics, 2006, Volume: 5, Issue:6 Topics: Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Membrane; Cisplatin; Culture Media, Serum-Free; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Fibronectins; GTP-Binding Proteins; Humans; Immunoprecipitation; Integrin beta Chains; Melanoma; Protein Glutamine gamma Glutamyltransferase 2; RNA, Small Interfering; Signal Transduction; Survival Rate; Transglutaminases	2006
Craniofacial fibrous dysplasia and hypophysial microadenoma with Hodgkin's lymphoma: unusual involution of an extensive case. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2006, Volume: 64, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease Progression; Doxorubicin; Female; Fibrous Dysplasia of Bone; Hodgkin Disease; Humans; Mandibular Diseases; Pituitary Neoplasms; Prolactinoma; Vinblastine	2006
Gliomatosis cerebri treatment in 11 elderly patients. Journal of experimental & clinical cancer research : CR, 2006, Volume: 25, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Lomustine; Magnetic Resonance Imaging; Male; Neoplasms, Neuroepithelial; Procarbazine; Survival Rate; Temozolomide	2006
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-01, Volume: 13, Issue:7 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins	2007
[Our experiences in treating patients with Hodgkin disease in the last decade]. Orvosi hetilap, 2007, Apr-15, Volume: 148, Issue:15 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Cyclophosphamide; Dacarbazine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Hungary; Male; Mechlorethamine; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine	2007
Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult. AIDS (London, England), 2008, Jan-02, Volume: 22, Issue:1 Topics: Adult; Anti-HIV Agents; Antibiotics, Antineoplastic; Antiretroviral Therapy, Highly Active; Bleomycin; Dacarbazine; Disease Progression; Doxorubicin; Fluorodeoxyglucose F18; HIV Infections; Hodgkin Disease; Humans; Male; Positron-Emission Tomography; Thymus Gland; Treatment Outcome; Vincristine	2008
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival? Journal of neuro-oncology, 2008, Volume: 88, Issue:1 Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neurosurgical Procedures; Positron-Emission Tomography; Retrospective Studies; Survival; Temozolomide; Treatment Outcome	2008
Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2008, Volume: 88, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome	2008
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Patient Selection; Promoter Regions, Genetic; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins	2008
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer, 2008, Jul-15, Volume: 113, Issue:2 Topics: Adolescent; Adult; Aged; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Treatment Outcome	2008
Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. International journal of radiation oncology, biology, physics, 1997, Oct-01, Volume: 39, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Dacarbazine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Radiotherapy; Remission Induction; Salvage Therapy; Treatment Failure; Vinblastine; Vincristine	1997
Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer research, 1997, Nov-15, Volume: 57, Issue:22 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cysteinyldopa; Dacarbazine; Disease Progression; Female; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms	1997
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Survival Rate; Vinblastine	1998
Syndrome of inappropriate secretion of antidiuretic hormone in a patient affected by metastatic melanoma. Melanoma research, 1998, Volume: 8, Issue:4 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Facial Neoplasms; Fatal Outcome; Frontal Lobe; Humans; Inappropriate ADH Syndrome; Lymphatic Metastasis; Male; Melanoma; Middle Aged	1998
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients. British journal of cancer, 1999, Volume: 81, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Division; Cyclin A; Dacarbazine; Disease Progression; Doxorubicin; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Prognosis; Prospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Vincristine	1999
High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer, 2000, May-01, Volume: 88, Issue:9 Topics: Administration, Inhalation; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Confounding Factors, Epidemiologic; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; Interleukin-2; Lung Neoplasms; Male; Melanoma; Recombinant Proteins; Remission Induction; Reproducibility of Results; Safety; Treatment Outcome	2000